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Immune surveillance of cancer cells is facilitated by the Natural Killer Group 2D (NKG2D)
receptor expressed by different lymphocyte subsets. It recognizes NKG2D ligands that
are rarely expressed on healthy cells, but upregulated by tumorigenesis, presenting a
target for immunological clearance. The molecular mechanisms responsible for NKG2D
ligand regulation remain complex. Here we report that cancer cell metabolism supports
constitutive surface expression of the NKG2D ligand MHC class I chain-related proteins
A (MICA). Knockout of the N-glycosylation gene N-acetylglucosaminyltransferase V
(MGAT5) in HEK293 cells induced altered metabolism and continuous high MICA
surface expression. MGAT5 knockout cells were used to examine the association of
cell metabolism and MICA expression through genetic, pharmacological and metabolic
assays. Findings were verified in cancer cell lines. Cells with constitutive high MICA
expression showed enhanced spare respiratory capacity and elevated mitochondrial
efflux of citrate, determined by extracellular flux analysis and metabolomics. MICA
expression was reduced by inhibitors of mitochondrial function, FCCP and etomoxir
e.g., and depended on conversion of citrate to acetyl-CoA and oxaloacetate by
ATP citrate lyase, which was also observed in several cancer cell types. Assay for
Transposase-Accessible Chromatin using sequencing (ATAC-seq) analysis revealed that
upregulated MICA transcription was associated with an open chromatin structure at
the MICA transcription start site. We identify mitochondria and cytoplasmic citrate
as key regulators of constitutive MICA expression and we propose that metabolic
reprogramming of certain cancer cells facilitates MICA expression and NKG2D-
mediated immune recognition.
Keywords: cancer metabolism, tumor immunology, MHC class I chain-related proteins A, citrate, ATP citrate
lyase, Natural Killer Group 2D
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GRAPHICAL ABSTRACT | MGAT5 knockout (KO) in HEK293 cells induces metabolic changes resulting in increased intracellular UDP-GlcNAc, increased
glycolysis, enhanced spare respiratory capacity and higher citrate flux from the mitochondria. MGAT5 KO cells express constitutively high MICA, mainly regulated on
the transcriptional level through opening of the chromatin at the MICA promoter. MICA expression in MGAT5 KO cells is dependent on citrate turnover and histone
acetylation. Blocking citrate flux inhibits MICA expression in numerous cancer cell lines, and we propose that this is a central metabolic regulation of MICA and
immune surveillance.
INTRODUCTION
Natural killer (NK) and CD8+ T cells monitor autologous
cells for markers of tumorigenesis and stress. These immune
cells express the NKG2D receptor that recognizes NKG2D
ligands (NKG2DLs) upregulated on the surface of transformed
cells (1). NKG2DL expression is in many ways a double-
edged sword. Upregulation of NKG2DLs on cancer cells
enhance NK cell infiltration and promote cancer cytotoxicity
(2, 3). Conversely, numerous cancer cells maintain chronic
NKG2DL expression and evade immune elimination by
down-modulating and impairing NKG2D receptor signaling
(4–7).
Cancer cells that block NKG2DL surface expression to
evade immune recognition and clearance, can be treated with
stress-inducers such as histone deacetylase inhibitors (HDACi’s),
heat-shock or short-chain fatty acids (SCFAs) that upregulate
NKG2DLs (8). To date, studies have primarily focused on
delineating transient NKG2DL induction whereas not much is
known about regulation of their constitutive expression.
Metabolic reprogramming is a central hallmark of cancer.
Cancer cells use aerobic glycolysis that was initially believed
to be a result of dysfunctional mitochondria (9); however,
later advances have shown that cancer cells often use aerobic
glycolysis alongside mitochondrial oxidative phosphorylation
(OXPHOS) (10). Mitochondria are not merely the powerhouse
of the cell, but also provide metabolites for anabolic pathways
necessary for cell growth. Citrate can be exported from the
tricarboxylic acid (TCA) cycle for biosynthetic purposes. In
the cytosol, citrate is cleaved by ATP citrate lyase (ACLY) to
generate acetyl-CoA and oxaloacetate (OAA) (11, 12). Citrate
is an inhibitor of glycolysis, thus to maintain high aerobic
glycolysis, cancer cells require low cytoplasmic citrate (13).
Moreover, conversion of citrate by ACLY is a critical regulator
of gene transcription by producing acetyl-CoA for histone
acetylation (14). Several of these cancer-associated metabolic
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properties are shared with other highly proliferating cells, such
as activated T cells.
Expression of NKG2DLs is associated with hyperproliferation
(8) and thus with highly active metabolism. Two studies have
linked NKG2DL expression to active glycolysis (15, 16), whereas
one study reports that inhibition of glycolysis increased basal
NKG2DL expression in breast cancer cell lines (17, 18). These
studies emphasize a link to proliferative cell metabolism, and
suggest that the role of glycolysis in NKG2DL regulation is
context-specific.
NKG2DLs fall into two groups, the UL-16 binding protein
1-6 (ULBP1-6) and the MHC class I chain-related proteins A
and B (MICA and MICB). Surface expression of each NKG2DL
is regulated individually and at all levels of protein biogenesis
(8). We have previously shown that surface expression of
specific MICA alleles depends on N-glycosylation (19, 20).
N-acetylglucosaminyltransferase V (MGAT5) is an oncoprotein
catalyzing the formation of β-1,6-branched N-glycans that
promote surface retention of glycoproteins (21), but it is not
known if MGAT5 regulates surface expression of MICA. Growth
factor receptors are examples of MGAT5 substrates, and MGAT5
overexpression is associated with growth, adhesion, invasion
and metastasis of cancer (22–26). Inhibition of MGAT5 reduces
tumor growth, enhances the anti-tumor responses by CD4+ T
cells and macrophages, and promotes Th1 differentiation (27, 28).
In this study we examine the metabolic regulation of the
NKG2DL MICA. We discover that MICA was increased after
MGAT5 knockout (KO) in a metabolically dependent way, and
use this as a model to investigate the regulatory mechanisms
of constitutive MICA expression. We find that glycolysis and
mitochondrial export of citrate promotes constitutive MICA
transcription in MGAT5 KO cells, a regulation that was also
shown in several MICA-expressing cancer cells. In particular,
increased MICA transcription was associated with altered
chromatin accessibility of the MICA promoter. Our findings
suggest that citrate drives a metabolic stress that modulates
chromatin accessibility to facilitate basal MICA transcription and
thereby regulate immune surveillance.
MATERIALS AND METHODS
Animals
Female NMRI mice 6 to 10-weeks old (Taconic, Lille Skensved,
Denmark) were used, and all studies were performed in
accordance with the Danish Act on Animal Experimentation,
which implements Directive 2010/63/EU on the protection of
animals in scientific research. The studies were approved by the
Animal Experimentation Inspectorate, Ministry of Environment
and Food, Denmark (License No. 2017-15-0201-01262). Health
monitoring was carried out in accordance with Federation for
Laboratory Animal Science Associations guidelines.
Reagents, Pharmacological Inhibitors,
and DNA Constructs
Pharmacological compounds from Sigma-Aldrich were
N-acetyl-D-glucosamine (GlcNAc, A3286), PUGNAc (A7229),
2-deoxy-D-glucose (2DG, D6134), carbonyl cyanide 4-
(trifluoromethoxy)phenylhydrazone (FCCP, C2920), UK-5099
(PZ0160), bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl
sulfide (BPTES, SML0601), potassium hydroxycitrate tribasic
monohydrate (HC, 59847), sodium dihydrogencitrate (234265),
sodium acetate (S5636), oxaloacetic acid (OAA, O4126),
6-Mercaptopurine monohydrate (6-MP, 852678), azaserine
(A4142), 5-aminoimidazole-4-carboxamide ribonucleotide
(AICA-R, A9978), N-Acetylcysteine (NAc, A9165), sodium
propionate (P1880), sodium butyrate (B5887), DMSO (D2438),
PBS (D8537). Etomoxir sodium salt was purchased from
Cayman Chemicals (Ann Arbor, MI, United States, 828934-
41-4). BMS303141 was from Tocris Bioscience (Bristol,
United Kingdom, 4609).
The GFP-Myc-MICA∗018 and MICA∗008 vectors, containing
the coding sequences of MICA∗018 or MICA∗008 allele
downstream of a generic leader, a GFP cassette, and a myc
tag, were provided by Dr. M. Wills (University of Cambridge,
Cambridge, United Kingdom) (29). pGL3-Basic (pGL3B)
luciferase vector was purchased from Promega (Promega,
Madison, WI, United States, E1751). MICA-firefly luciferase
promoter vectors and SV40-renilla luciferase promoter vector
were provided by Prof. C. O’Callaghan (University of Oxford,
Oxford, United Kingdom) (30).
Purification of Peripheral Blood
Lymphocytes
Human peripheral blood mononuclear cells (PBMCs) were
isolated by Histopaque-1077 (Sigma-Aldrich, St. Louis, MO,
United States, 10771) separation from buffy coats obtained
from healthy blood donors (The Capital Region Blood Bank,
Copenhagen University Hospital, Copenhagen, Denmark). To
obtain peripheral blood lymphocytes (PBLs), PBMCs were
depleted from monocytes by incubation with Dynabeads
(Invitrogen, Carlsbad, CA, United States, 11041), as previously
described (31). PBLs were activated in RPMI1640 without
glucose (Gibco, Gaithersburg, MD, United States, 11879-
020) supplemented with 10% dialyzed fetal bovine serum
(FBS) (F9665), 2 mM penicillin/streptomycin (P4333), 2 mM
L-Glutamine (G7513), 1 mM sodium pyruvate (S8636) and either
10 mM D-glucose (G8769) or 10 mM D-galactose (G6404),
all purchased from Sigma-Aldrich. PBLs were activated with
CD3/CD28 beads (Invitrogen, 11132D) and 20U/mL hIL-2
(Peprotech, Rocky Hill, NJ, United States, 200-02) for 3 days.
On day 3, PBLs were treated with 20 ng/mL FR901228 (National
Cancer Institute, Bethesda, MD, United States) for 18 h.
Cell Line Cultivation and Proliferation
Human embryonic kidney-derived HEK293 cells, the prostate
cancer cell line PC-3 and the keratinocyte-derived cell line
HaCaT were purchased from American Type Culture Collection
(ATCC, Manassas, VA, United States). NKG2D reporter cell
CT312 and the 2B4 parental cell line were kindly provided
by Chiwen Chang, Trowsdale Lab, Cambridge University.
The breast cancer cell lines MDA-MB231 and MCF-7 were
provided by Dr. José Moreira (Department for Veterinary
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Disease, University of Copenhagen, Denmark) and Henrik
Leffers (The State Hospital, Copenhagen, Denmark), respectively.
The cervical cancer cell line HeLa was provided by Jesper
Jurlander (The State Hospital, Copenhagen, Denmark). The
melanoma cells SK-MEL28, FM55m1, FM78 and FM86, and
the human colon adenocarcinoma cell lines HT29 and SW480
were provided by Dr. Per thor Straten (Herlev University
Hospital, Denmark). HEK293, MDA-MB231 and MCF-7 cells
were cultured in DMEM with GlutaMAX (Gibco, 31966047).
HeLa, HaCaT, PC-3, FM55m1, FM78, FM86, SK-MEL28, and
SW480 were cultured in RPMI1640 (Sigma-Aldrich, R5886),
and HT29 were cultured in McCoy’s 5A medium (Sigma-
Aldrich, M8403). Media were supplemented with 10% FBS and
2 mM penicillin/streptomycin. 2 mM L-Glutamine was added
to RPMI1640 and McCoy’s 5A. For long-term cell culture in
glucose/galactose, cells were cultured in DMEM medium without
glucose (Gibco, 11966025), supplemented with 10% dialyzed
FBS, 2 mM penicillin/streptomycin, 1 mM sodium pyruvate, and
10 mM glucose/galactose. All cells were kept at culture conditions
37◦C and 5% CO2 and were passaged every 2–3 days.
For proliferation assay, WT and MGAT5 KO cells were
seeded in 1 × 105 or 2 × 105 cells/well. For each experiment,
cells were counted in triplicate wells after 24 and 48 h using
the Bio-Rad TC20 automated cell counter (Bio-Rad, Hercules,
CA, United States).
Gene Editing
MGAT5 KO cells were generated by zinc finger nuclease
targeting in HEK293 cells and subsequent cloning and selection
was performed as described previously (32, 33). HEK293
cells were transfected with mRNA (Sigma-Aldrich) or 5 µg
of endotoxin free plasmid DNA using nucleofection on an
Amaxa Nucleofector (Lonza, Copenhagen, Denmark). MGAT5
KO clones were selected by loss of reactivity with L-PHA,
and clones were confirmed to have Mgat5 mutations using
PCR and sequencing.
Lentiviral-mediated gene transfer was performed with an
MGAT5 encoding vector constructed by inserting the MGAT5
sequence (generated as a blunt-end PCR product from a vector
from HW, University of Copenhagen, Copenhagen, Denmark)
into an entry vector system using the pENTR Directional
TOPO Cloning Kit (Invitrogen, K2435-20/K3500-20) following
manufacturer’s protocol. TOPO clonal reaction entry vectors
were transformed into Mach-T1 chemically competent E. coli
using heat-shock and S.O.C. medium followed by selection.
PCR inserts were confirmed by sequencing at Eurofins MWG
Operons (Luxembourg). Colonies were amplified and plasmids
were purified with Nucleobond Xtra Midi kit (Macherey-Nagel,
Duren, Germany, 740410). MGAT5 sequences were inserted
into pLX302 lentiviral destination vector with LR CLonase II
enzyme mix (Invitrogen, 11789). After proteinase K treatment
constructs were transformed into DH5α using heat-shock and
S.O.C. medium. Selected clones were amplified and DNA was
purified using Nucleobond Xtra Midi kit. Destination vectors
were checked for insertion using BsrGI digestion at 55◦C.
MGAT5-coding lentiviral particles were packaged in HEK293T
cells transfected with a mix of 4 µg psPAX2 vector (packaging
vector), 2 µg pCMV-VSVG (envelope vector), 5 µg pLX302
vector carrying MGAT5, and 25 µl CaCl2 to a final volume of
250 µl. The DNA mixture was complexed with 250 µL 2x HBS
under constant air flow, and the transfection mix was added
dropwise to 2 × 106 HEK293T cells in antibiotic-free medium.
Cell culture medium was harvested 4 days after transfection and
viral particle preparations were prepared by centrifugation at
5000 × g for 5 min. Lentiviral particles were added to cells and
incubated for 24 h. Cells were cultivated in puromycin (1 µg/mL)
selection medium for 2 weeks. Functional MGAT5 expression
was validated by L-PHA binding.
Transient Transfection
Transient transfections were performed as described previously,
using Amaxa Nucleofector device (Lonza) (34). DNA was
introduced to 2 × 106 cells in 100 µl Nucleofector solution V
(Lonza, VCA-1003) and pulsed using the nucleofector program
Q-001. For GFP-myc-tagged MICA∗008 and MICA∗018
constructs, cells were transfected with 1 µg DNA and analyzed
the next day. Transfection with shRNAs or luciferase promoter
constructs was carried out by calcium-phosphate transfection.
Briefly, DNA/RNA were prepared in 10 µl CaCl2 (2.5M)
and adjusted to a final volume of 100 µl. DNA mixture was
complexed with 100 µl 2x HBS (HEPES, NaCl, Na2HPO4)
and added dropwise to 2 × 106 cells. Scrambled siRNA
control, siIDH1 and siIDH2 ON-TARGET plus SMART pools
were purchased from GE Healthcare Dharmacon (Lafayette,
CO, United States).
Functional Assays
For NKG2D down-modulation, PBLs were isolated as described
above, followed by depletion of CD4+ cells using CD4 antibody
(eBioscience, San Diego, CA, United States, 16-0049) and
Dynabeads Mouse pan-IgG (Invitrogen, 11041). CD4+-depleted
PBLs were cultured in RPMI1640 (Sigma-Aldrich, R5886)
supplemented with 10% human serum (Sigma-Aldrich, H3667),
2 mM penicillin/streptomycin, 2 mM L-Glutamine and 10 ng/mL
hIL-15 (Peprotech, 200-15) for 3 days to enrich for NK/CD8+
T cells. NKG2D down-modulation assay was performed as
previously described (35). NKG2D ligands on effector cells
(HEK293 WT or MGAT5 KO cells) were incubated with blocking
NKG2D-Fc (R&D Systems, Minneapolis, MN, United States,
1299-NK) or control IgG1-Fc (R&D Systems, 110-HG) 8 µg/mL
for 30 min at 4◦C. Effector cells and target cells (NK/CD8+
T cells) were mixed at indicated effector:target ratios and spun
down 2 min 90 × g to allow conjugate formation. After 2 h co-
cultivation, NK/CD8+ T cells were analyzed for NKG2D surface
expression by flow cytometry using Accuri C6 flow cytometer
(BD Bioscience, Franklin Lakes, NJ, United States).
For the reporter cell assay, the NKG2D-reporter cell line
2B4-CT312 and the parental control 2B4 cell line (target cells)
(36) were mixed with effector cells (WT or MGAT5 KO cells)
that were either blocked with NKG2D-Fc or control IgG1-Fc as
described above. Effector and target cells were co-cultivated at
different E:T ratios for 14–16 h. GFP expression of target cells
was assessed with Accuri C6 flow cytometer. For in vivo assay,
target cells were labeled with Vybrant DiD cell-labeling solution
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(Invitrogen, V22887) according to manufacturer’s protocol, and
injected intraperitoneally together with WT or MGAT5 KO
cells in a 1:1 ratio, 20 × 106 of each. 4–6 mice were used
per group. Target cells were harvested after approximately 18 h
with peritoneal lavage and NKG2D activation of DiD-positive
reporter cells were assessed as GFP expression with Accuri
C6 flow cytometer.
Lactate and dNTP Measurements
Concentrations of L-Lactate was measured enzymatically with
Randox colorimetric assay according to manufacturer’s protocol
(Randox, Crumlin, United Kingdom, LC2389). Reaction and
analysis was performed on an Advia 1800 Chemistry System
(Siemens, Munich, Germany).
dNTP levels were determined in 2 × 106 cells harvested with
trypsinization and pelleted by centrifugation for 1200 × g for
5 min followed by resuspension of cell pellets in 60% methanol,
frozen in liquid nitrogen and boiled at 100◦C for 3 min. Samples
were evaporated until dryness in a speedvac and whole cell levels
of dTTP dATP, dCTP, and dGTP were determined using the DNA
polymerase assay previously described (37).
LC-HRMS Metabolite Profiling
To determine intracellular metabolite levels, cell pellets from
1 × 106 cells were resuspended in 750 µl of cold methanol
after 5 min sonication. Samples were prepared by 15 s
vortex followed by 15 min equilibration at room temperature.
After centrifugation at 13000 × g for 10 min at 4◦C,
400 µl supernatants were collected, transferred to Ultrafree-MC
Centrifugal filter devices (Merck Millipore Ltd., Cork, Ireland),
and centrifuged at 10000 × g for 4 min at 4◦C. From this, 100 µl
was transferred to LC vials, and 30 µl of each sample was pooled
to a mixed QC sample.
LC-HRMS was performed on a 1290 Infinity II ultra-
high performance liquid chromatography (UHPLC) system
coupled to a 6550 iFunnel quadrupole-time of flight (Q-TOF)
mass spectrometer equipped with a dual AJS electrospray
ionization source (Agilent Technologies, Santa Clara, CA,
United States). Polar metabolites were separated on a SeQuant
ZIC-HILIC (Merck, Darmstadt, Germany) column 100 Å
(100 mm × 2.1 mm, 3.5 µm particle size) coupled to a guard
column (20 mm × 2.1 mm, 3.5 µm particle size) and an inline-
filter. Mobile phases consisted of 0.1% formic acid in water with
(solvent A) and 0.1% formic acid in acetonitrile with (solvent B).
The elution gradient used was as follows: isocratic step at 95% B
for 1.5 min, 95% B to 40% B in 12 min and maintained at 40% B
for 2 min, then decreasing to 25% B at 14.2 min and maintained
for 2.8 min, then returned to initial conditions over 1 min, and the
column was equilibrated at initial conditions for 7 min. The flow
rate was 0.3 mL/min, injection volume was 2 µL and the column
oven was maintained at 25◦C. The acquisition was obtained
with a mass range of 50–1200 m/z for, where full scan high-
resolution data is acquired at three alternating collision energies
(0 eV, 10 eV and 30 eV). Positive and negative raw LC-HRMS
files were independently processed with an in-house developed
PCDL library for polar metabolites using Profinder version B.06
(Agilent Technologies). Identification of reported compounds
was assessed by accurate mass and retention time (AMRT) plus
fragment identification at two collision energies (10 and 30 eV).
Detailed acquisition methodology has been described previously
(38, 39). UDP-GlcNAc/UDP-GalNAc detected peak (screened by
expected calculated mass) could be of either compound as these
two sugars could not be separated chromatographically, hence
has been reported as a putative metabolite pending confirmation.
Extracellular Flux Analysis
The Seahorse XFe96 extracellular flux analyzer (Agilent
Technologies) was used to measure OCR and ECAR on HEK293
cells. Cells were seeded at the density 2 × 104 cells/well ∼24 h
before the experiment. One hour prior to assay run, cells were
rinsed and switched to XF media (Agilent Technologies) with
1 mM sodium pyruvate and 10 mM glucose or galactose and
incubated at 37◦C CO2-free incubator. For the mitochondrial
stress tests, OCR was measured under basal conditions, and
during sequential injection of 1 µM oligomycin (Sigma-Aldrich,
495455), 1 µM FCCP (Sigma-Aldrich, C2920), and 0.5 µM
rotenone (Rot, Sigma-Aldrich, R8875) + 0.5 µM antimycin
A (AA, Sigma-Aldrich, A8674). Reported basal respiration is
calculated from the third measuring point with OCR after Rot
and AA subtracted, ATP-coupled respiration display OCR after
oligomycin subtracted from the third measuring point, and
maximal respiration is OCR after FCCP with OCR after Rot
and AA subtracted.
For measuring the effect of HC, OCR was assessed 2 h after an
injection of 15 mM HC.
13C6-Glucose Tracing Experiment
1 × 106 cells were incubated for 1 h in DMEM medium without
glucose supplemented with 10% FBS, 1 mM sodium pyruvate,
and 25 mM uniformly labeled [U-13C]-Glucose (Cambridge
Isotope Laboratories, Tewksbury, MA, United States, CLM-
1396). Incubation medium samples were collected and cleared by
centrifugation 300× g for 5 min. Cells were washed and detached
sterically. Intracellular metabolites were extracted in 70% ethanol,
and centrifuged at 20.000 × g for 20 min (4◦C) to separate
the soluble extract (supernatant) from the insoluble components
(pellet). Cell extracts and medium samples were lyophilized
and reconstituted in water for subsequent biochemical analyses.
Extract samples were adjusted to pH 1-2 with HCl and evaporated
to dryness under nitrogen flow. Analytes were extracted into an
organic phase (96% ethanol/benzene) followed by derivatization
with 14% DMF/86% MTBSTFA with a modified procedure from
(40). Standards containing unlabeled metabolites of interest and
cell extracts were separated and analyzed in a gas chromatograph
(Agilent Technologies 7820A chromatograph, J&W GC column
HP-5MS, parts no. 19091S-433) coupled to a mass spectrometer
(Agilent Technologies, 5977E). The isotopic enrichment of the
metabolites of interest was corrected for natural abundance of 13C
using the unlabeled standards and calculated according to (41).
Data are presented as labeling (%) of M+ X, where M is the mass
of the unlabeled molecule and X is the number of labeled C-atoms
in a given metabolite (42).
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Western Blotting
Proteins were extracted using RIPA buffer (Thermo Scientific,
Waltham, MA, United States, 89901) and proteinase/phosphatase
inhibitor cocktail (Thermo Scientific, 1861281) for 30 min
on ice. Lysates were sonicated 2 times for 15 s and cleared
by centrifugation at 13,000 rpm for 10 min at 4◦C. Protein
extracts were denatured at 70◦C for 10 min in NuPAGE sample
buffer and DTT (Sigma-Aldrich, 646563). Proteins were resolved
using 4–12% SDS-PAGE gels (Invitrogen) and transferred to
nitrocellulose membranes (Invitrogen, IB301001) using the iBlot
device (Invitrogen). For total protein stain, membranes were
washed in ddH2O and stained with REVERT protein stain
solution (LI-COR Biosciences, Lincoln, NE, United States, 926-
11015) according to manufacturer’s protocol. Membranes were
blocked in TBST blocking buffer (LI-COR Biosciences, 927–
50000), probed with primary antibodies in TBS w. 0.1% Tween
20 and 5% BSA overnight on a shaker at 4◦C, and washed in
TBS + 0.1% Tween 20. Secondary antibody was from LI-COR
(LICOR Biosciences, 926–32212) and signals were visualized
by the Odyssey Fc Imaging System (LI-COR Biosciences).
O-GlcNacylation was detected with RL2 O-GlcNAcylation
antibody (Abcam, Cambridge, United Kingdom, ab2739), ATP
citrate lyase (ACLY) was detected with rabbit ACLY antibody
(Cell Signaling; 4332), and ACLY phosphorylation with rabbit
phospho-ACLY (Ser455) antibody (Cell Signaling; 4331).
Flow Cytometry
Adherent cells were detached in PBS w. 1 mM EDTA (Invitrogen,
15575-038) or by pipetting. Cell surface staining was done as
previously described (43), and cells were analyzed on Accuri
C6 flow cytometer (BD Bioscience). Antibodies used for this
study were: MICA (R&D systems, FAB1300A), ULBP2/5/6 (R&D
Systems, FAB1298P), NKG2D (R&D Systems, FAB139A), ULBP1
(R&D Systems, FAB1380P), ULPB3 (R&D Systems, FAB1517A),
ULBP4 (R&D Systems, FAB6285A), MICA/B (BD Bioscience,
558352), ICAM-1 (Leinco Technologies, C170), mouse IgG1
anti-myc-tag (Merck Millipore, 05724), MICB (R&D Systems;
MAB1599) or IgG2b isotype control (R&D Systems; MAB004)
detected with secondary anti-mouse IgG (Biolegend, San Diego,
CA, United States, 405308). Binding of fluorescently labeled
AF647-L-PHA (Invitrogen, L32457) and FITC-E-PHA (Vector
Laboratories, Burlingame, CA, United States, FL-1121) was used
to measure surface levels of complex N-glycans. All isotype
controls were purchased from BD Bioscience.
For staining with mitochondrial probes, neutral lipid stains
or 2-NBDG uptake, 5 × 105 cells seeded the day prior to
experiment were washed once in PBS and incubated for 15 min
at 37◦C and 5% CO2 in warm growth medium containing 25 nM
tetramethylrhodamine methyl ester perchlorate (TMRM, Sigma-
Aldrich, T5428), 10 nM MitoTracker Green FM (Invitrogen,
M7514), or for 2 h in growth medium with 5 µM 2-NBDG
(Invitrogen, N13195). Bodipy 493/503 (Invitrogen, D3922) was
diluted in warm serum-free medium in a 1:7000 dilution and
shaken vigorously to solubilize the lipids, immediately before
loading into the cells for 15 min. Cells were washed twice in
PBS+ 2% FBS and detached sterically prior to analysis.
The soluble NKG2D–Fc receptor (1299-NK, R&D Systems)
and IgG1–Fc (110-HG; R&D Systems) were labeled with Zenon
Alexa Fluor 647 against human IgG1 (Z25408; Invitrogen) prior
to staining of melanoma cells.
Data were acquired with an Accuri C6 instrument using
Accuri C6 software, and analyzed in Flowlogic v7.2.1 (Inivai
Technologies, Mentone, VIC, Australia) by gating on viable
cells in forward-side-scatter plots (FSC/SSC) followed by
single cell gating by area-height-scatter plots (FSC-A/FSC-
H). Geometric mean fluorescent intensity (MFI) values are
displayed in figures as MFI, or with corresponding isotype control
subtracted as1MFI.
Real Time PCR Analysis
Total RNA was extracted by phase separation in TRIzol-
chlorophorm and purified on Direct-zol spin-columns (Zymo
Research, Irvine, CA, United States) according to manufacturer’s
protocol. cDNA was generated using SuperScript cDNA
synthesis kit (Invitrogen) under standard PCR conditions.
Following primer sequences were used for quantitative
RT-PCR with Brilliant SYBR Green qPCR Master Mix
Kit: MICA (MICA_F: TGGCAGACATTCCATGTTTCTG,
MICA_R: CTCGTCCCAACTGGGTGTTG), ULBP2 (ULBP
2_F: CAGAGCAACTGCGTGACATT, ULBP2_R: GGCCAC
AACCTTGTCATTCT), IDH1 (IDH1_F: CTATGATGGTGA
CGTGCAGTCG, IDH1_R: CCTCTGCTTCTACTGTCTTGCC),
IDH2 (IDH2_F: AGATGGCAGTGGTGTCAAGGAG, IDH
2_R: CTGGATGGCATACTGGAAGCAG), GLUT1 (GLUT1_F:
CTGCTCATCAACCGCAAC, GLUT1_R: CTTCTTCTCCCG
CATCATCT), GLUT2 (GLUT2_F: TACATTGCGGACTTCTG
TGG, GLUT2_R: AGACTTTCCTTTGGTTTCTGG), GLUT3
(GLUT3_F: CAGCGAGACCCAGAGATG, GLUT3_R: TTGG
AAAGAGCCGATTGTAG), GLUT4 (GLUT4_F: TGGGCTT
CTTCATCTTCACC, GLUT4_R: GTGCTGGGTTTCACCTC
CT), and RPLP0 as housekeeping gene (RPLP0_F:
CCTCGTGGAAGTGACATCGT, RPLP0_R: CATTCCCCC
GGATATGAGGC). Real-time qPCR was performed on Bio-
Rad CFX96 Real-time Thermal Cycler C1000 Touch, and all
transcripts were normalized to housekeeping RPLP0 transcript.
Luciferase Reporter Assay
Cells were transiently transfected, using calcium-phosphate
transfection as described above, with firefly luciferase promoter
vectors (1 µg) and an SV40-promoter driven renilla luciferase
vector (0.5 µg). Cells were harvested and snap frozen 24 h
post transfection. Pellets were lysed in Dual-Glo Luciferase
Reagent (Promega, E2920) and firefly luciferase activity was
analyzed by luminometer Microbeta II (PerkinElmer, Waltham,
MA, United States). Renilla luciferase activity was recorded by
the instrument after subsequent addition of 1:1 volume Dual-
Glo Stop & Glo (Promega, E2920). To correct for transfection
efficiency, firefly luciferase signals were normalized to SV40
renilla luciferase signals of corresponding sample.
ATAC-Seq
ATAC-seq was performed as described previously (44). For
each cell line, 50,000 cells were harvested from 3 separate
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cultures and used to prepare tagmented chromatin (3 replicates
of WT and 3 replicates of MGAT5 KO cell lines, 6 samples
total). Quality of PCR-amplified sequencing libraries was assessed
using a Tapestation 2200 instrument with high sensitivity DNA
screentapes (Agilent). Libraries were sequenced as paired end
reads on a single lane of an Illumina HiSeq4000 flow cell.
Resulting reads were aligned to the GRCh37/hg19 reference
genome using Rsubread (45), and alignments were filtered to
remove low quality, duplicate, and mitochondrial reads. Peaks
were called using MACS2 (46) on merged reads from all
samples, and differential peak accessibility between cell lines was
determined using edgeR (47) with a threshold false discovery
rate of 5%. Transcription factor binding motifs enriched in
differentially accessible peaks were identified using HOMER (48).
H3K4me3 ChIP-seq data were downloaded from ENCODE1 and
are available under accession ENCFF756EHF.
Quantification and Statistical Analysis
Results are presented as mean± SEM. Differences were analyzed
for statistical significance using Prism 7 or 8 (GraphPad Software,
La Jolla, CA, United States). Statistical analysis was performed as
stated in figure legends, using unpaired t-test in 1A, 1C, 1E, 3E-F,
3H, 5C, 7A, 7E-F, paired t-test in 4F-G, 7D, multiple t-test in 1B,
1D, 3D, 4A-B, one sample t-test in 2A-C, 3C, 4C, 4E, 7G, two-way
ANOVA in 3A, 5D-F, 5H-I, 6A, 6E, 7h-I, or one-way ANOVA in
5G. Level of statistical significance was determined by ∗p < 0.05,
∗∗p< 0.01 and ∗∗∗p< 0.001, ∗∗∗∗p< 0.0001.
RESULTS
MGAT5 Knockout Increases NKG2DL
Expression and Activates NKG2D in vitro
and in vivo
Regulation of constitutive MICA expression remains largely
unknown. Surface expression of certain MICA alleles depends
on N-linked glycosylation (19, 20, 49). We questioned whether
the cancer-associated glycosyltransferase MGAT5 is required for
MICA expression. To assess the role of MGAT5 in regulation
of NKG2DL surface expression, MGAT5 KO clones were
generated in HEK293 cells. Remarkably, MGAT5 KO resulted
in a permanently increased surface expression of the NKG2DLs
MICA, MICB, and ULBP2/5/6 compared with parental wildtype
(WT) cells (Figure 1A). To confirm MGAT5 KO we measured
binding of Leukoagglutinin from P. vulgaris (L-PHA) that binds
specifically to MGAT5-modified N-glycans. As expected, L-PHA
binding was reduced, whereas binding of Erythroagglutinin
from P. vulgaris (E-PHA) that interacts with MGAT3-modified
N-glycans, was unaffected, thus verifying functional knockout
of MGAT5 (Figure 1A). Modification of MGAT5 expression
therefore associated with substantial changes in constitutive
expression of several NKG2DLs.
To verify the functionality of MGAT5 KO-induced NKG2DLs,
we tested NKG2D activation in a reporter cell line expressing
1https://www.encodeproject.org/
human NKG2D coupled to DAP10-CD3ζ signaling and Nuclear
factor of activated T cells (NFAT)-controlled GFP, ultimately
expressing GFP in response to NKG2D activation (36). NKG2D-
GFP activation was higher after co-cultivation with MGAT5
KO cells than with WT cells (Figure 1B), corresponding to the
increased NKG2DL expression in MGAT5 KO cells (Figure 1A).
The reporter cells without NKG2D (Supplementary Figure S1A)
remained inactivated, indicating that the activation was NKG2D-
mediated (Figure 1B). Moreover, blocking NKG2DLs with
soluble NKG2D-Fc receptor impaired the activation, further
validating NKG2D specificity (Supplementary Figure S1B).
To test if MGAT5 KO cells could activate NKG2D in vivo,
we adoptively injected NKG2D reporter cells together with WT
or MGAT5 KO cells into the peritoneum of NMRI mice and
measured GFP expression in reporter cells. In line with our
in vitro data, we observed a significant increase in NKG2D-GFP
activation by MGAT5 KO cells compared with WT cells. The
response was NKG2D-specific since the control reporter cells
were unaffected (Figure 1C). These data verify that MGAT5 KO-
induced NKG2DLs maintain their functional integrity in vivo.
NKG2D is down-modulated upon activation (50). To further
examine the functionality of NKG2DL expression caused
by MGAT5 KO, we assessed NKG2D downregulation after
receptor activation. NKG2D was further downregulated on
CD4+-depleted peripheral blood lymphocytes (PBLs) after co-
cultivation with MGAT5 KO cells than with WT cells, and this
downregulation was abolished by blocking NKG2DLs with a
soluble NKG2D-Fc receptor (Figure 1D). Combined, these data
indicate that KO of MGAT5 upregulates MICA and ULBP2/5/6,
resulting in NKG2D activation in vitro and in vivo.
To ensure that the MICA upregulation was a result of MGAT5
KO, we stably transfected MGAT5 into WT and MGAT5 KO
cells. L-PHA binding was restored within days after transfection,
confirming expression of functional MGAT5. Interestingly, it
took multiple passages for MICA expression to decrease to WT
levels (Figure 1E and Supplementary Figure S1C), suggesting
that MICA is regulated in response to a long-term adaptation to
altered MGAT5 expression.
UDP-GlcNAc Upregulates MICA
Expression
Long-term MGAT5 deficiency will likely result in aberrant
N-glycosylation and an accumulation of the MGAT5 donor
substrate UDP-N-acetylglucosamine (UDP-GlcNAc). To address
if MICA was regulated by a change in N-glycosylation in
MGAT5 KO cells, we assessed the post-translational regulation
of MICA by measuring surface expression of transgenically
expressed GFP-myc-tagged MICA under a cytomegalovirus
(CMV) promoter. The MICA alleles, MICA∗008 and MICA∗018
are distinctly regulated posttranslationally (19), and although
MICA∗008 was upregulated in MGAT5 KO cells, the regulation
was minor and unlikely to account for the profound change
in endogenously expressed MICA (Figures 1A, 2A). MICA
transcripts on the other hand, were highly increased in MGAT5
KO cells (Figure 2B), as well as ULBP2 mRNA (Supplementary
Figure S2A), suggesting that NKG2DLs are transcriptionally
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FIGURE 1 | MGAT5 knockout increases NKG2DL expression and activates NKG2D in vitro and in vivo. (A) Surface expression of NKG2D ligands and binding of
fluorescently labeled L-PHA (MGAT5 modifications) or E-PHA (MGAT3 modifications) on HEK293 wildtype (WT) and HEK293 MGAT5 knockout (KO) cells or isotype
control staining (Iso) analyzed by flow cytometry. Data are presented as histograms representative of at least three independent experiments and in bar graphs
showing mean fluorescence intensity (MFI). (B) In vitro NKG2D activation measured as GFP expression in NKG2D negative reporter cells (Control) and NKG2D
expressing (NKG2D) reporter cells (target cells) co-cultivated with WT or KO cells (effector cells) for 14–16 h at indicated effector:target (E:T) ratios. (C) NKG2D
activation in vivo measured on reporter cells as in (B) after activation by WT or KO at a 1:1 ratio in peritoneum of NMRI mice for approximately 18 h. GFP expression
in DiD-labeled reporter cells signifies NKG2D activation and is shown as GFP MFI values of cells from four-six mice per group. (D) NKG2D down-modulation was
assessed on NK/CD8+ T cells (target cells) after co-cultivation for 2 h with WT or KO cells (effector cells) at indicated effector:target ratios (E:T). NKG2DLs on target
cells were blocked with NKG2D-Fc (BL) or unblocked with IgG1-Fc (UN). The graph depicts surface expression of NKG2D presented relative to surface NKG2D
expression on target cells alone. (E) MICA surface expression (left) and L-PHA/E-PHA surface binding (right) after lentiviral introduction of MGAT5 into WT or KO
cells. MFI values from antibody staining were corrected for isotype background staining (1MFI). Statistical analysis was performed by unpaired t-tests in (A,C,E), and
multiple t-test with 5% FDR comparing WT and KO in (B,D). *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
regulated in MGAT5 KO cells. Notably, we found that the
MGAT5 substrate UDP-GlcNAc, although indistinguishable
from UDP-N-acetylgalactosamine (UDP-GalNAc) tended to
be higher in MGAT5 KO cells compared with WT cells
(Figure 2C). This prompted us to address whether UDP-
GlcNAc accumulation increased MICA mRNA. We found that
cultivation of cells in GlcNAc-supplemented medium, which
is known to increase intracellular UDP-GlcNAc through the
salvage pathway (51), increased MICA transcripts and MICA
surface expression, particularly in WT cells (Figure 2D and
Supplementary Figure S2B). Together, this suggests that MICA
is upregulated due to UDP-GlcNAc accumulation in MGAT5
KO cells by transcriptional regulation, and thus independently of
MICA N-glycosylation.
Glycolysis Supports MICA Expression in
MGAT5 KO Cells
Accumulation of UDP-GlcNAc can regulate gene transcription
directly as the donor substrate for O-GlcNAcylation, which
competes with phosphorylation of Ser/Thr on several enzymes
and transcription factors (52, 53). Moreover, UDP-GlcNAc
is synthesized from the hexosamine biosynthetic pathway
arising from glycolysis, and can regulate cell metabolism
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FIGURE 2 | UDP-GlcNAc upregulates MICA expression. (A) HEK293 wildtype
(WT) and HEK293 MGAT5 knockout (KO) cells were transfected with
GFP-myc-tagged MICA*008 or MICA*018 under CMV promoter and detected
on the surface the following day as surface myc-tag expression on
GFP-positive cells. Data are displayed as isotype-corrected mean
fluorescence intensity (1MFI) relative to WT from three-four independent
experiments. Dot plots are representative of all experiments. Grid is set to 5%
of corresponding isotype controls. (B) MICA mRNAs were analyzed by
quantitative RT-PCR in total RNA purified from WT and KO cells. MICA
expression was normalized to housekeeping gene RPLP0 and shown as ratio
relative to WT cells from six independent experiments.
(C) UDP-GlcNAc/UDP-GalNAc measurements from LC-HRMS analysis of
(Continued)
FIGURE 2 | Continued
intracellular metabolites in WT and KO cells are presented as relative peak
areas (a.u.) corresponding to UDP-GlcNAc or UDP-GalNAc.
Log10-transformed values from three experiments are shown as individual
dots. (D) MICA mRNA analyzed by quantitative RT-PCR in total RNA purified
from WT and KO cells after 8 days cultivation with indicated concentrations of
GlcNAc. MICA expression is normalized to housekeeping gene RPLP0 and
displayed as ratio relative to untreated WT cells from two independent
experiments. All data are displayed as mean ± SEM. Statistical analysis was
performed using one-sample t-test in (A,B), and unpaired t-test with Welch’s
correction in (C). **p < 0.01 and ***p < 0.001, p-value is presented in (C).
through N-glycosylation of nutrient transporters and
receptors (26).
We first explored if UDP-GlcNAc regulated MICA expression
through O-GlcNAcylation. O-GlcNAc is added enzymatically
to proteins by O-GlcNAc transferase (OGT) and removed by
O-GlcNAcase. Inhibition of either enzyme is known to impair
functional O-GlcNAcylation (54, 55). We blocked O-GlcNAcase
with PUGNAc, and found that this had no effect on MICA
expression (Figure 3A). In agreement with this, there was no
increase in total protein O-GlcNAcylation in MGAT5 KO cells
(Figure 3B). This indicates that O-GlcNAcylation is not a direct
regulator of MICA, although altered O-GlcNAcylation could still
be contributing to the long-term adaptation by modifying targets
further upstream of MICA transcription.
Next, we approached the metabolic alterations in MGAT5 KO
cells. Both MGAT5 and UDP-GlcNAc have been associated with
regulation of cell metabolism (56–59). We therefore investigated
whether glucose intake had changed in MGAT5 KO cells.
Indeed, these cells had an increased uptake of the glucose
analog 2-NBDG compared with WT cells, corresponding to
a transcriptional upregulation of glucose transporters GLUT1,
3 and 4 (Figures 3C,D). Furthermore, when we traced 13C6-
labeled glucose, we found that MGAT5 KO cells converted
glucose into intracellular lactate; however, the glucose-derived
lactate in MGAT5 KO cells was not secreted from the cells,
resulting in overall lower extracellular lactate (Figures 3E,F).
The increased uptake of glucose and conversion to intracellular
lactate in MGAT5 KO cells resembled elevated aerobic glycolysis,
which is one of the hallmarks of cancer and supports increased
growth and proliferation (60). Nevertheless, we found that WT
and MGAT5 KO cells proliferated at the same rate (Figure 3G).
Importantly, impairing glycolysis in MGAT5 KO cells with
2-deoxy-D-glucose (2DG) reduced MICA mRNA and surface
expression (Figure 3H and Supplementary Figure S3A). 2DG
inhibits the flux through glycolysis as well as the hexosamine
biosynthetic pathway. Addition of GlcNAc or D-mannose rescues
the hexosamine biosynthetic pathway (61), and we found
that it also restored MICA expression after 2DG inhibition
(Figure 3H and Supplementary Figure S3B), suggesting that
MICA expression in MGAT5 KO cells depends on glucose flux
to the synthesis of UDP-GlcNAc.
Recently, it was shown that purine biosynthesis was
critical for glucose-induced MICA expression (16). We
therefore tested if MICA expression in MGAT5 KO cells
was caused by enhanced purine biosynthesis, but MICA
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FIGURE 3 | Glycolysis supports MICA expression in MGAT5 KO cells. (A) HEK293 wildtype (WT) and HEK293 MGAT5 knockout (KO) cells were treated with
GlcNAcase inhibitor PUGNAc for 18 h prior to flow cytometry analysis of MICA surface expression. (B) O-GlcNAcylation of whole cell proteins from WT and KO cells
quantified by western blotting of O-GlcNAcylation with the monoclonal RL2 antibody and total protein stain. Data are representative of three independent
experiments. (C) Uptake of fluorescent glucose analog 2-NBDG in WT and KO cells after 2 h incubation with medium containing 2-NBDG (5 µM) was analyzed by
flow cytometry. Mean fluorescent intensity (MFI) values are displayed as percentage of WT. (D) mRNA of glucose transporters GLUT1, 3, and 4 analyzed by
quantitative RT-PCR in total RNA purified from WT and KO cells are presented as mRNA relative to housekeeping gene (HKG) RPLP0. (E) Intracellular and
extracellular glucose-derived lactate in WT and KO cells were quantified by GC mass spectrometry after 1 h incubation in culture medium containing 13C6-Glucose.
13C incorporation in lactate is shown as percent lactate M + 3 out of total lactate fraction in cell lysates or supernatants. (F) Total extracellular lactate measurements
from cell culture supernatants conditioned by WT or KO cells for 12 h. (G) Cell counts from start concentration of 1 × 105 or 2 × 105 cells/well counted after 24 and
48 h. (H) MICA surface expression on KO cells were treated with 2DG (20 mM) with or without GlcNAc (25 mM) for 22–24 h. Data of untreated (UT) samples share
values from UT samples in Figures 7E,F. All MFI values from antibody staining were corrected for isotype background staining (1MFI). All graphs are displayed as
mean ± SEM from three independent experiments. Statistical analysis was performed by two-way ANOVA with Sidak’s multiple comparison test in (A), one-sample
t-test in (C), multiple t-test in (D), and unpaired t-test with Welch’s correction used when SD was unequal in (E,F,H). *p < 0.05, ***p < 0.001, and ****p < 0.0001.
expression in MGAT5 KO cells was unaffected by the
purine biosynthesis inhibitor 6-mercaptopurine (6-MP)
and even slightly increased by the inhibitor azaserine
(Supplementary Figures S3C,D). Moreover, the precursor
for de novo purine biosynthesis AICA-R upregulated MICA
expression in both WT and MGAT5 KO cells (Supplementary
Figure S3E), further suggesting that the constitutive MICA
expression on MGAT5 KO cells is not caused by consistently
increased purine biosynthesis. Overall, these data indicate
that glycolytic flux to the hexosamine biosynthetic pathway
supports constitutively upregulated MICA expression
in MGAT5 KO cells.
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MICA Expression Requires Functional
Adaptation of Mitochondria in MGAT5
KO Cells
The hexosamine biosynthetic pathway plays a key role in rewiring
cancer metabolism (62). We therefore evaluated mitochondrial
OXPHOS in an extracellular flux assay that monitors oxygen
consumption rate (OCR) in response to specific inhibitors of
oxidative metabolism (Figures 4A,B). Basal respiration and
ATP-coupled respiration were unaltered in MGAT5 KO cells
(Figures 4A,B). Remarkably, the maximal respiration was more
than twice as high in MGAT5 KO cells compared with WT cells
(Figures 4A,B), demonstrating an enhanced spare respiratory
capacity (SRC). To determine if mitochondrial functionality was
necessary for MICA expression, we impaired the mitochondrial
membrane potential with the uncoupler FCCP, and found that
it reduced MICA mRNA and cell surface expression in MGAT5
KO cells (Figure 4C and Supplementary Figure S4A). The TCA
cycle can be supplied with metabolites from glycolysis, fatty acid
oxidation and amino acid catabolism. Certain immunological
functions have been associated with specific TCA cycle substrates
(63). To test if MGAT5 KO cells supported MICA expression
by oxidation of either of these resources, we inhibited the
mitochondrial pyruvate carrier (MPC), import of fatty acids
by carnitine palmitoyltransferase 1 (CPT1) or glutaminolysis
by glutaminase (GLS) with the pharmacological inhibitors
UK5099, etomoxir and BPTES, respectively (Figure 4D). The
color of the MPC inhibitor obstructed flow cytometric analysis,
but we found that it had no effect on MICA transcription
(Figure 4D). The CPT1 inhibitor etomoxir reduced MICA
transcript levels and surface expression in MGAT5 KO cells,
whereas inhibition of GLS had no effect (Figure 4D and
Supplementary Figure S4B). MICA mRNA levels in WT cells
were not affected by etomoxir, but the response in WT cells
was otherwise comparable (Supplementary Figures S4B,C).
These data suggest that constitutive MICA expression in
MGAT5 KO cells depends on fatty acid oxidation. Accordingly,
MGAT5 KO cells also had increased accumulation of neutral
lipids, providing plenty of substrate for fatty acid oxidation
(Figure 4E). However, etomoxir has recently been shown to
have inhibitory effects on OXPHOS independent of fatty acid
oxidation, suggesting that MICA expression may be independent
of fatty acid oxidation, but supporting the importance of
functional mitochondria (64). We further tested if MGAT5 KO-
induced MICA expression was regulated by the mitochondrial
production of reactive oxygen species (ROS), but the antioxidant
N-Acetylcysteine (NAc) potentiated rather than reduced MICA
expression (Supplementary Figure S4D). Furthermore, MGAT5
KO cells had a higher membrane potential measured with
the mitochondrial directed probe TMRM, but no difference
in mitochondrial mass, quantified with the fluorescent probe
MitoTracker (Figures 4F,G), demonstrating that the enhanced
SRC was not caused by an increased mitochondrial mass.
Together, our data indicate that mitochondrial properties are
altered in MGAT5 KO cells evident by an increased membrane
potential and enhanced SRC, and disrupting mitochondrial
integrity reduced MICA expression. Mitochondrial function is
thus critical for the increased MICA expression in MGAT5 KO
cells, but not by producing ROS.
Mitochondrial Export of Citrate
Facilitates MICA Expression in MGAT5
KO Cells
In a metabolite screen, we found that most detected and
confirmed intracellular metabolites were more abundant in
MGAT5 KO cells compared with WT cells (Figure 5A). When
measuring forward scatter by flow cytometry, we furthermore
found that MGAT5 KO cells were larger in size (Figure 5B).
Additionally, MGAT5 KO cells had higher dNTP levels,
specifically dTTP and dATP (Figure 5C). Combined with the
lipid accumulation (Figure 4E), this indicates that MGAT5 KO
cells accumulate metabolites compared with WT cells.
In contrast, citrate was the only metabolite that was lower in
MGAT5 KO cells (Figure 5A). Cancer cells support increased
growth and proliferation by exporting mitochondrial citrate to
the cytoplasm. When citrate exits the mitochondria through the
citrate/malate-exchanger, it can be converted to acetyl-CoA and
OAA by the cytosolic ACLY. The citrate analog hydroxycitrate
(HC) is a non-functional competitive inhibitor of ACLY. We
found no difference in ACLY expression or the activating
ACLYS455 phosphorylation (65) between WT and MGAT5 KO
cells (Supplementary Figure S5A). However, treatment with
HC resulted in citrate accumulation that was more pronounced
in MGAT5 KO cells compared with WT cells (Figure 5D),
suggesting that the lower levels of citrate in MGAT5 KO
cells is caused by a high citrate turnover (Figures 5A,D). To
further validate that MGAT5 KO cells had increased turnover
of citrate, we blocked ACLY to inhibit citrate export from
mitochondria, thereby forcing citrate to be oxidized in the TCA
cycle. Indeed, only MGAT5 KO cells increased OCR significantly
after HC treatment (Figure 5E). Moreover, HC reduced surface
MICA expression in MGAT5 KO cells (Figure 5F), and this
reduction was validated by another ACLY inhibitor BMS303141
(Supplementary Figure S5B). HC decreased MICA mRNA levels
as well, suggesting a transcriptional regulation (Supplementary
Figure S5C). OAA can readily be converted to malate and re-
enter the mitochondria to keep the citrate/malate-exchanger
running, and addition of OAA rescued the expression of
MICA after ACLY inhibition (Figure 5G), suggesting that
MICA expression depends on preserved flux of citrate from
the mitochondria. Supporting this, we found that knockdown
of isocitrate dehydrogenase 2 (IDH2) that converts isocitrate
to α-ketoglutarate in the mitochondria, potentiated MICA
expression in MGAT5 KO cells (Figure 5H and Supplementary
Figure S5D). This indicates that increasing citrate efflux by
blocking the TCA cycle downstream of citrate augments MICA
expression. Furthermore, knockdown of the cytosolic IDH1
likewise upregulated MICA in MGAT5 KO cells (Figure 5H
and Supplementary Figure S5D). Finally, MICA expression
was amplified with the addition of citrate in MGAT5 KO cells
but not WT cells (Figure 5I and Supplementary Figure S5E),
indicating that the metabolic reprogramming in MGAT5 KO cells
has provided a capacity to translate cytosolic citrate to MICA
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FIGURE 4 | MICA expression requires functional adaptation of mitochondria in MGAT5 KO cells. (A,B) Mitochondrial stress test performed on HEK293 wildtype (WT)
and HEK293 MGAT5 knockout (KO) cells and analyzed by Seahorse XF analysis. (A) Fluctuations in oxygen consumption rate (OCR) after addition of oligomycin
(1 µM), FCCP (1 µM) and rotenone/antimycin A (Rot/AA) (0.5 µM). (B) Shows quantifications of basal respiration (third measuring point) and maximal respiration
(OCR after FCCP addition) adjusted for non-mitochondrial oxygen consumption (OCR after Rot/AA), and ATP-coupled respiration (the drop in OCR after oligomycin).
Data shows mean ± SEM of three independent experiments. (C) MICA mRNA analyzed by quantitative RT-PCR in total RNA purified from KO cells after 4 h
treatment with DMSO or the mitochondrial uncoupler FCCP (2.5 µM). MICA expression is normalized to housekeeping gene RPLP0 and displayed as ratio relative to
vehicle (DMSO) as mean ± SEM of four independent experiments. (D) MICA expression after inhibition of TCA cycle substrates: MICA mRNA analyzed by
quantitative RT-PCR in total RNA purified from KO cells after 4 h treatment with DMSO or the pyruvate import inhibitor UK5099 (200 µM). MICA expression is
normalized to housekeeping gene RPLP0 and displayed as ratio relative to DMSO control (left). MICA surface expression analyzed by flow cytometry in KO cells after
18 h treatment with fatty acid import inhibitor etomoxir (500 µM) (middle) or glutaminolysis inhibitor BPTES (5 µM) (right). Mean fluorescent intensity (MFI) values are
corrected for isotype background staining and displayed as percent of DMSO control. All three graphs display mean ± SEM from three independent experiments.
(E) Neutral lipid stain with Bodipy 493/503 probe was loaded to WT and KO cells and detected by flow cytometry. Grid is set at ∼5% according to stained WT cells.
Dot plots are representative of four independent experiments. (F,G) Mitochondrial membrane potential (F) and mitochondrial mass (G) in WT and KO cells measured
with the fluorescent probe TMRM (25 nM) or MitoTracker Green FM (10 nM), respectively. The bar graphs display mean ± SEM of MFI values from three-five
independent experiments. Statistical analysis was performed by multiple t-test with a 5% false discovery rate in (A,B), and one-sample t-test in (C,E), and paired
t-test in (F,G). **p < 0.01 and ***p < 0.001.
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FIGURE 5 | Mitochondrial export of citrate facilitates MICA expression. (A) Intracellular metabolites in HEK293 wildtype (WT) and HEK293 MGAT5 knockout (KO)
cells quantified by LC-HRMS. Relative peak areas (a.u.) of identified metabolites (N:35) from three experiments are pooled, expressed as ratios (KO/WT) and sorted
accordingly. (B) Cell size of WT and KO cells measured as forward scatter (FSC) by flow cytometry, representative of at least three independent experiments.
(C) Deoxynucleotides (NTPs) in whole cell lysates of WT and KO were quantified by DNA polymerase assay. The bar graph displays mean ± SEM from three
independent experiments. (D) Intracellular citrate levels in WT and KO cells after 6 h treatment with PBS (UT) or hydroxycitrate (HC, 30 mM) quantified by LC-HRMS.
The graph displays relative peak areas (a.u.) as mean ± SEM from three experiments. (E) Oxygen consumption rate (OCR) by WT or KO cells 2 h after HC (15 mM)
injection by Seahorse XF instrument. Percent of OCR at the time of HC injection is presented as mean ± SEM from five independent experiments. (F) MICA surface
expression on WT and KO cells analyzed by flow cytometry after 42 h treatment with indicated concentrations of HC. The bar graph displays isotype corrected MICA
expression (1MFI) as mean ± SEM from three independent experiments. (G) MICA surface expression on WT and KO cells analyzed by flow cytometry after 18 h
treatment with HC (15 mM) with or without indicated concentrations of oxaloacetate (OAA). 1MFI is shown as percent of corresponding treatment without HC, and
graph displays mean ± SEM from three independent experiments. (H) MICA surface expression on WT and KO cells 3 days post transfection with scrambled siRNA
(siCtr), siIDH1 or siIDH2. The bar graph displays 1MFI as mean ± SEM from three independent experiments. (I) MICA surface expression on WT and KO cells after
18 h treatment with indicated concentrations of citrate. The bar graph displays 1MFI as mean ± SEM from three independent experiments. Statistical analysis was
performed by unpaired t-test in (C), two-way ANOVA with Bonferroni’s multiple comparison test in (D–F,I,H), and one-way ANOVA with Dunnett’s multiple
comparison test in (G). *p < 0.05, **p < 0.01, and ***p < 0.001.
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expression. Combined, this suggests that MICA expression in
MGAT5 KO cells is maintained by mitochondrial efflux of citrate.
Increased Chromatin Accessibility at the
MICA Transcription Start Site in MGAT5
KO Cells
Conversion of citrate by ACLY regulates proliferation and gene
expression by providing acetyl-CoA for fatty acid synthesis
and histone acetylation (14). Inhibiting the synthesis of fatty
acids did not impair MICA expression in MGAT5 KO cells
(Supplementary Figure S6A). Similar to citrate, acetate can
increase the acetyl-CoA pool and has previously been shown
to induce MICA expression in cancer cells (15). In line with
this, we found that acetate potentiated MICA expression in
MGAT5 KO cells (Supplementary Figure S6B), indicating that
MICA expression in MGAT5 KO cells could be responsive to
increased acetyl-CoA. To test if MICA expression depended
on protein acetylation, we inhibited histone acetyl transferases
(HATs) with anachardic acid, and this impaired MICA expression
in MGAT5 KO cells significantly (Figure 6A). Since histone
acetylation regulates chromatin accessibility that modulates gene
transcription, we next investigated if this was altered in MGAT5
KO cells. Indeed, ATAC-seq analysis revealed that MGAT5 KO
cells had a region−196 to+ 264 bp from the MICA transcription
start site where the chromatin was significantly more open than
in WT cells (Figure 6B), indicating increased accessibility for
transcriptional activity. Analysis of chromatin accessibility across
the whole genome demonstrated that several of the top 10 motifs
that were enriched in MGAT5 KO cells were binding sites for
factors related to the activating protein-1 (AP-1) transcription
factor complex (Figure 6C) which is known to bind to the MICA
promoter (66). Reciprocally, downregulated peaks comprised
consensus motifs for the transcriptional repressor CTCC-binding
factor (CTCF) and the CTCF-like Brother of the Regulator of
Imprinted Sites (BORIS) that are known regulators of chromatin
structure (Figure 6D) (67, 68). These findings suggest that
CTCF-mediated chromatin condensation in WT cells may be
abrogated in MGAT5 KO cells, possibly due to metabolite-
mediated epigenetic changes.
The region of the MICA promoter that displays increased
chromatin accessibility in MGAT5 KO cells is known to be
involved in the transcriptional regulation of MICA and consistent
with this, it is rich in H3K4me3 marks (Figure 6B). This
region comprises binding sites for heat shock factor, Nuclear
factor kappa-light-chain-enhancer of activated B cells (NF-κB),
Sp1, and AP-1 transcription factor complex (Supplementary
Figure S6C) (30, 43, 66). To investigate if MICA transcription
was upregulated due to increased activity of transcription factors
binding to this region, we measured luciferase activity in a
MICA promoter construct expressed in WT or MGAT5 KO
cells. The MICA promoter was constitutively active in both
WT and MGAT5 KO cells compared with the promoter-
less construct pGL3B, but luciferase activity was comparable
in WT and MGAT5 KO cells (Figure 6E), indicating that
the raised MICA transcript levels in MGAT5 KO cells are
not driven by increased transcription factor activity at this
site. Further, MICA promoter constructs with mutations in
either NF-κB binding site, heat shock element (HSE) or both
(30), were equally expressed in WT and MGAT5 KO cells
(Supplementary Figure S6D). Histone acetylation is associated
with open transcriptionally active chromatin and the histone
deacetylase inhibitor FR901228 further upregulated MICA
expression in MGAT5 KO cells (Supplementary Figure S6E).
Transient stimulation with the short-chain fatty acid propionate
also upregulated MICA expression in both WT and MGAT5
KO cells, indicating that acute stress-induced MICA regulation
may be distinct from regulation of constitutively expressed
MICA (Supplementary Figure S6E). These findings suggest that
constitutive MICA expression in MGAT5 KO cells is influenced
by the increased openness of the chromatin structure around the
MICA transcription start site.
Hydroxycitrate Reduces MICA
Expression in Activated T Cells and
Multiple Cancer Cells
An increasing variety of histone modifications has been reported
to modify chromatin accessibility. A recent study demonstrated
that lactate can be used for lactylation of histones and thus
regulate gene transcription (69). Since MGAT5 KO cells had
reduced secretion of lactate (Figures 3D,E), intracellular lactate
could modify chromatin structure like acetyl-CoA. We tested
if MICA expression in MGAT5 KO cells was predominantly
dependent on changed glycolytic or mitochondrial function. To
distinguish the effects, we forced WT cells to lower glycolysis and
increase mitochondrial respiration by cultivation in galactose-
medium as previously described (70–72) (Supplementary
Figure S7A). Galactose is processed at a slower rate than
glucose, and cells thereby favor mitochondrial respiration
for energy production. Interestingly, WT cells in galactose
increased MICA mRNA levels after long-term cultivation (over
30 passages) (Figure 7A). MICA surface expression; however,
was only marginally upregulated (Figure 7B). This indicates
that increased mitochondrial function can facilitate MICA
transcription, but mitochondrial activity is not sufficient for
upregulating MICA surface expression to the levels seen in
MGAT5 KO cells, which also have functional glycolysis. Similar
to MGAT5 KO cells, we found that WT cells cultivated in
galactose medium had increased SRC (Figure 7C). Moreover,
their MICA expression was impaired by treatment with HC
(Supplementary Figure S7B) and amplified by treatment with
citrate (Supplementary Figure S7C), supporting that cells
cultivated in galactose have gained an enhanced capacity to
express MICA, resembling MGAT5 KO cells.
Activated T cells are some of the few healthy cells that are
capable of expressing MICA (73, 74). Furthermore, some T cell
subsets shift to a cancer-like metabolism upon activation (75).
We therefore investigated if expression of MICA/B by activated
T cells was potentiated by enforcing mitochondrial activity with
galactose-cultivation. We activated PBLs with CD3/CD28 and IL-
2 for 3 days in glucose or galactose medium prior to stimulation
with the HDACi FR901228. We observed an increase in basal
MICA/B expression in galactose-cultivated PBLs as well as a
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FIGURE 6 | Increased chromatin accessibility at the MICA transcription start site in MGAT5 KO cells. (A) MICA surface expression analyzed by flow cytometry in
HEK293 wildtype (WT) and HEK293 MGAT5 knockout (KO) cells after 24 h treatment with the HAT inhibitor anachardic acid (75 µM). The bar graph displays isotype
corrected MICA expression (1MFI) as mean ± SEM from three independent experiments. (B–D) Chromatin accessibility in WT and KO cells analyzed by ATAC-seq.
(B) Chromatin accessibility of WT and KO at chromosome 6 spanning the MICA gene. Normalized ATAC-seq data are aligned with MICA transcripts from RefSeq
and ENCODE H3K4me3 ChIP-seq data from HEK293 cells. Genomic regions with significant differences in chromatin accessibility are highlighted in blue. The
ATAC-seq track is representative of three independent experiments. (C) Top 10 enriched motifs in peaks upregulated in MGAT5 KO cells. (D) Top 10 enriched motifs
in peaks downregulated in MGAT5 KO cells. (E) MICA promoter activity in WT and KO cells analyzed as luciferase activity 24 h after transfection with promoter-less
firefly luciferase construct (pGL3B) or firefly luciferase-coupled MICA promoter (MICA). Firefly luciferase activity is normalized to an SV40 promoter-coupled renilla
luciferase co-transfected into the cells. The bar graph displays mean ± SEM from four independent experiments. Statistics in (A,E) are analyzed using two-way
ANOVA with Bonferroni’s multiple comparison test. **p < 0.01.
prominent amplification of HDACi-induced MICA/B expression
compared with glucose-cultivated PBLs (Figure 7D). This
expression was blocked by HC (Supplementary Figure S7D).
Combined, this indicates that the metabolic properties of
galactose-cultivation supports constitutive MICA transcription,
much like MGAT5 KO cells, supporting that mitochondria can
drive basal MICA expression even at low glycolytic conditions.
In line with this, we found that MICA inhibition after
blocking glycolysis in MGAT5 KO cells could be completely
annulled by simultaneous addition of citrate (Figure 7E). In
comparison, MICA expression after HC, could not be recovered
by citrate or GlcNAc supplementation (Figure 7F), highlighting
that citrate turnover is critical for MICA expression and
distal to glycolytic regulation of MICA in MGAT5 KO cells.
Interestingly, we also discovered that the NKG2DLs ULBP2/5/6,
which were also upregulated in MGAT5 KO cells (Figure 1A),
were not significantly regulated by modulating mitochondrial
functionality, citrate metabolism, or histone acetylation, using
etomoxir, HC or anachardic acid, respectively (Supplementary
Figures S5F–H). To elucidate if cancer cells with constitutive
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FIGURE 7 | Continued
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FIGURE 7 | Hydroxycitrate reduces MICA expression in activated T cells and multiple cancer cells. (A) MICA mRNA analyzed by quantitative RT-PCR in total RNA
purified from HEK293 cells after more than 30 passages in glucose (Glc) and galactose (Gal). MICA expression is normalized to housekeeping gene RPLP0 and
displayed as mean ± SEM from six independent experiments. (B) MICA surface expression analyzed by flow cytometry of Glc and Gal cells at basal levels. Dot plots
are representative of at least three independent experiments. Grid is set to ∼5% of corresponding isotype control stainings. (C) Mitochondrial stress test on HEK293
cultivated in Glc or Gal under same conditions as in Figure 4A. The graph is baselined to measuring point three and displays mean ± SEM from two independent
experiments. (D) MICA/B surface expression of peripheral blood lymphocytes (PBLs) activated for 3 days in Glc or Gal growth medium prior to 18 h treatment with
FR901228 (20 ng/mL). Grids in dot plots are set to ∼5% of corresponding isotype control staining and dot plots are representative of seven different donors. The bar
graph displays mean ± SEM of isotype-corrected MICA/B MFI (1MFI) from seven donors. Left panel is zoomed in on the difference between untreated Glc and Gal
PBLs. (E,F) HEK293 MGAT5 knockout (KO) cells were treated with (E) 2DG (20 mM) or (F) hydroxycitrate (HC) (15 mM) in addition to PBS (UT), citrate (10 mM), or
GlcNAc (25 mM) for 22–24 h. Bar graphs display MICA surface expression as mean ± SEM of 1MFI values from three independent experiments. Data of UT
samples share values with UT samples in Figure 3H. (G) MICA surface expression in several cancer cell lines after 18 or 42 h treatment with HC (10 mM). 1MFI
values are normalized to UT control and shown as mean ± SEM from at least three independent experiments. (H,I) MICA surface expression (H) and NKG2D-fc
binding (I) in cancer cell lines after 2.5 h treatment with HC (10 mM) prior to 18 h stimulation with FR901228 (FR, 20 ng/mL) or sodium butyrate (But, 5 mM). Bar
graphs display MICA surface expression as mean ± SEM of 1MFI values (H), or NKG2D-fc surface binding as ± SEM of 1MFI normalized to untreated (UT) control
(I), from three independent experiments. Statistical analysis was performed by unpaired t-test with Welch’s correction in (A,E,F), ratio paired t-test in (D),
one-sample t-test in (G), and two-way ANOVA with Bonferroni’s multiple comparison test (H,I). *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
MICA expression shared the same dependency on citrate
conversion to maintain MICA expression, we treated different
cancer cell lines with HC. Indeed, MICA expression on
melanoma cell lines FM55m1, FM86, FM78, and SK-MEL-
28, colorectal cancer cell lines HT29 and SW480, as well as
HeLa and HaCaT cells were sensitive to ACLY inhibition by
HC (Figure 7G). However, breast cancer cell lines MCF-7 and
MDA-MB231, and prostate cancer cell lines PC-3 were either
unresponsive to HC or increased MICA expression (Figure 7G).
MICA expression in the HC-unresponsive MDA-MB231 cells
were also unaffected by cultivation in galactose (Supplementary
Figure S7E), suggesting that some cancer cells hold metabolic
properties that have uncoupled MICA expression from citrate-
metabolism. Upregulation of MICA on melanoma and colorectal
cancer cell lines by treatment with HDACi FR901228 or butyrate,
was significantly inhibited by HC treatment (Figure 7H),
resulting in reduced binding of NKG2Dfc soluble receptor, as
shown in FM78, FM86, and SK-MEL28 (Figure 7I). HC did
not impair ICAM-1 expression, except form a minor reduction
in FM55m1 and HT-29 cells (Supplementary Figure S7F),
suggesting that citrate flux is essential for MICA expression in
certain cancer cells.
Altogether, our data demonstrate that constitutively increased
MICA expression in MGAT5 KO cells relied on metabolic
alterations, and suggest that MICA expression was upregulated
through an enhanced chromatin accessibility. A similar
phenotype was observed in cancer cells that share a sensitivity
to the ACLY inhibitor HC, and we propose that citrate drives
basal MICA expression by providing acetyl-CoA for histone
acetylation that can modify chromatin structure around the
MICA transcription start site. Metabolic reprogramming of
cancer cells can thus be monitored by the immune system
through increased NKG2DL expression.
DISCUSSION
Altered metabolism is a recognized hallmark of cancer cells that
has promised therapeutic opportunities for more than a decade
(76). We have shown that citrate exported from mitochondria
drives expression of MICA, a stress-induced ligand for the
immune activating NKG2D receptor in multiple cancer cell lines,
and we put forward a model where constitutive MICA expression
is facilitated by metabolic regulation of chromatin structure.
Through examination of glycosylation-dependent MICA, we
found that KO of the N-acetylglucosaminyltransferase MGAT5
increased MICA expression and thereby increased activation
of NKG2D in vitro and in vivo. However, this is caused
by altered metabolism rather than changes in MICA N-
glycosylation. MICA∗008 and MICA∗018 are distinctly regulated
by N-glycosylation, but both were expressed on the surface of
both WT and MGAT5 KO cells, indicating that neither depend
on complex N-glycan formation. HEK293 cells are homozygous
for the MICA∗008 allele (77), and we found that MICA∗008
was upregulated posttranslationally in HEK293 MGAT5 KO
cells, suggesting that there could be a contribution of allele-
specific regulation. However, the posttranslational upregulation
was not sufficient to describe the vast upregulation of endogenous
MICA expression in MGAT5 KO cells was predominantly
regulated transcriptionally. MGAT5 expression is in many cases
associated with tumor progression and metastatic potential
(22, 24, 78, 79). Inhibition of cancer-associated MGAT5 is
considered a potential therapeutic target, and has led to immune
activation in a breast cancer mouse model (27). In line with
this, our data suggest that MGAT5 KO increases NKG2DLs,
which would support cancer elimination in response to MGAT5
inhibition. Furthermore, MGAT5 KO has been associated
with inflammatory diseases such as colitis (80), which also
correlates with increased expression of NKG2DLs and thereby
increased immune activation. Nevertheless, we found that MICA
regulation was a long-term response to MGAT5 KO, hence,
other early events may interfere and influence immunity before
MICA expression is established. Further studies are required
to pinpoint the direct involvement of MGAT5 and NKG2DLs
in cancer and autoimmune diseases. This model; however,
gives a framework for understanding constitutive regulation of
NKG2DLs, and MGAT5 KO cells have here proven useful for
investigating relevant cell metabolic features driving constitutive
MICA expression.
Others have shown that MGAT5 overexpression increases
surface expression of growth factor receptors through
glycosylation and thereby regulate growth (25, 26, 56, 81).
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Notably, our MGAT5 KO cells also show increased growth
and glucose uptake, possibly due to an excessive compensating
feedback mechanism when adapting to the lack of MGAT5,
which is likely driven by changes in the transcriptome, since
glucose transporters were upregulated transcriptionally. We
found that long-term UDP-GlcNAc accumulation in MGAT5
KO cells was important for MICA expression, which could
contribute to the new metabolic phenotype. MGAT5 KO cells
have increased aerobic glycolysis and lipid accumulation,
suggesting enhanced lipid biosynthesis, compared with WT cells.
These are all traits of cancer metabolism and could infer that
MGAT5 KO cells resemble cancer cells metabolically (82).
Anti-cancer immune cells rely on some of the same metabolic
pathways as cancer cells for exercising effector functions, and
therapeutic strategies that target cancer metabolism can thus
impede anti-cancer immunity (83). It is therefore critical to
delineate metabolic pathways that are essential for cancer
cells selectively or even promote immune surveillance. We
found that metabolic changes in MGAT5 KO cells support
MICA expression, since inhibition of glycolysis or disruption
of mitochondrial integrity reduced chronic MICA expression.
We argue that mitochondrial function is central for regulating
constitutive MICA expression in MGAT5 KO cells and
CD3/CD28-activated PBLs, since lowering glycolysis with culture
medium deplete of glucose and supplemented with galactose
raised MICA expression. Although constitutive MICA expression
in MGAT5 KO cells was dependent on functional mitochondria,
basal OXPHOS was similar in WT and MGAT5 KO cells,
indicating that basal OXPHOS is not driving MICA expression.
Mitochondria export citrate to the cytosol for biosynthetic
purposes, and this is increased in cancer cells (10). Cytosolic
citrate inhibits phosphofructokinase of the glycolysis; therefore,
maintaining a low level of cytosolic citrate is crucial for
sustaining cancer-related aerobic glycolysis (13). We found
that citrate flux was high in MGAT5 KO cells, maintaining
low citrate levels that can support the increased aerobic
glycolysis. The citrate efflux from mitochondria was critical
for MICA expression in MGAT5 KO cells, and citrate
supplementation could potentiate MICA expression. A cancer-
associated mutation of IDH1 that generates the oncometabolite
2-hydroxyglutarate from cytoplasmic α-ketoglutarate (expected
to diminish cytoplasmic citrate) has previously been shown to
inhibit expression of the NKG2DLs ULBP1 and ULBP3 (84).
This corresponds with our findings that cytoplasmic citrate is
a driver of NKG2DL expression, and in further support of
this we found that knockdown of IDH1 or IDH2 potentiated
MICA expression in MGAT5 KO cells. Intracellular citrate is
associated with cancer aggressiveness in prostate cancer cells
and is a suggested biomarker for response to therapy (13, 85).
Citrate administration sensitizes cancer cells to chemo therapy
in vitro and therefore has an anti-cancer therapeutic potential (13,
86). Our data indicate that citrate may also contribute to tumor
immune surveillance by upregulating NKG2DLs in metabolically
reprogrammed cells, thus promoting an anti-tumor response.
However, we found that MICA expression depended on citrate
conversion to acetyl-CoA and OAA by ACLY. Furthermore,
we found that acetate-induced MICA was impaired by ACLY
inhibition (Supplementary Figure S6B), in line with previous
findings showing that acetate can enter that TCA cycle and
expand the acetyl-CoA pool through ACLY cleavage of citrate
(87). ACLY is often overexpressed in cancer, and inhibition of
ACLY is known to impair tumorigenesis, and impede cancer
stemness and growth (11, 12, 88, 89). We did not detect increased
expression levels of ACLY in MGAT5 KO cells compared with
WT cells, suggesting that the citrate flux is driven by changes in
metabolite levels possibly promoted by to the increased glucose
uptake. We found that basal MICA expression in MGAT5 KO
cells as well as several cancer cells, is downregulated in response
to ACLY inhibition with HC. HC likewise impaired HDACi
and SCFA-induced MICA in cancer cells. The consequences of
constitutive MICA expression are poorly understood since it
may have dual roles on anti-tumor immunity (90). Treating
cancer with HC and thus reducing MICA expression can result
in tumor immune evasion. Conversely, some cancers exhaust
anti-cancer immunity by persistent high NKG2DL expression
(4–7, 91), here HC treatment may be a selective treatment
option. This hypothesis, however, needs further experimental
verification, since the current study relies on in vitro findings.
HC inhibition of MICA expression was selective to some tumors.
Interestingly, prostate cancer cell line PC-3 was the only cell type
that upregulated MICA in response to HC. Prostate cells are
known to have atypical citrate metabolism because they produce
and secrete large amount of citrate as a component of semen
(92). Hence, to implement this in future treatment approaches
it is important to define the metabolic prerequisites that couples
citrate to MICA expression.
Mechanistically, ACLY regulates histone acetylation by
controlling availability of acetyl-CoA that modulates chromatin
accessibility and gene transcription. We show that MGAT5 KO
cells have more open chromatin at the MICA transcription
start site and that MICA expression was reduced by HAT
inhibition, indicating that increased MICA mRNA is promoted
by increased MICA transcription. Plasmid DNA does not form
proper chromatin (93) And transcription of luciferase reporter
plasmids was not upregulated in MGAT5 KO cells, indicating that
MGAT5 KO-induced elevated MICA expression is maintained by
increased chromatin accessibility rather than increased activation
of transcription factors able to bind to this site. Constitutive
MICA expression in MGAT5 KO cells may thus be driven
by omnipresent transcription factors activating MICA due to
the higher chromatin accessibility. It is well established that
acetyl-CoA availability regulates global acetylation levels and
gene expression (94). However, a mechanism controlling gene
specificity has been unclear. After the discovery that acetyl-
CoA-producing enzymes, including ACLY, can locate to the
nucleus (95, 96), it has been proposed that localized production
of acetyl-CoA facilitates site-specific acetylation (97). This
was not explored in this study, but is a relevant course for
future investigations.
Differences between expression of individual NKG2DLs in
different cell types complicates the studies of NKG2DLs. It
remains to be understood what determines if a cell can
express NKG2DLs. Here, we provide evidence for a possible
instructive role of the cell metabolism in regulating MICA,
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proposing that the permanent metabolic shift in cancer cells
and activated T cells primes cells for MICA expression. Our
data indicate that citrate holds a major regulatory role in basal
MICA expression, likely by regulating chromatin accessibility
through acetylation (Graphical abstract). It is noteworthy that
the NKG2DLs ULBP2/5/6 likewise were highly upregulated in
our cell model, but regulated in a distinct manner yet to be
delineated. We recently published that the TCA intermediate
fumarate upregulates ULBP2/5/6 in ROS-dependent manner
(98), which together emphasize that the cell metabolism can
convey a stress signal through NKG2DLs. Defining the metabolic
control of NKG2DLs can help us design strategies targeting
cancer metabolism without impairing immune surveillance.
Furthermore, constitutive MICA expression is associated with
increased inflammation and autoimmune diseases (99). This
study investigates metabolic control of the immune stimulatory
ligand MICA with a focus on metabolism as a hallmark of cancer.
It is therefore tempting to speculate that metabolic control
of constitutive MICA expression also is important in cases of
metabolism-associated chronic inflammation.
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be
made available by the authors, without undue reservation.
ETHICS STATEMENT
The animal study was reviewed and approved by the Animal
Experimentation Inspectorate, Ministry of Environment
and Food, Denmark.
AUTHOR CONTRIBUTIONS
SM, MMe, MMa, LA, and SS: conceptualization. SM, MMe,
MMa, AB, SJ, MH, BA, CD, ES, ED, TH, DL, and LA:
methodology. SM, BA, CD, ES, ED, and TH: formal analysis.
SM, MMe, MMa, AB, SJ, MH, RH, BA, CD, ES, ED, and
TH: investigation. CW, CO’C, HW, and SS: resources. SM
and SS: writing – original draft. SM, MMe, RH, MMa, AB,
SJ, MH, BA, CD, LR, ES, ZG-H, ED, CW, TH, DL, CO’C,
HW, LA, and SS: writing – review and editing. SM and TH:
visualization. SS: supervision. CD, CW, CO’C, HW, and SS:
funding acquisition. All authors contributed to the article and
approved the submitted version.
FUNDING
This work was supported by funding from the Novo Nordisk
Foundation (NNF15CC0018346 for SS), the Independent
Research Fund Denmark (DFF-FSS 4183-00389A for SS),
European Commission (H2020-ERC GAP-772735 for HW), the
Danish National Research Foundation (DNRF107 for HW), and
Dagmar Marshalls Fond for CD.
ACKNOWLEDGMENTS
We thank Dr. Chiwen Chang (Department of Pathology,
University of Cambridge, United Kingdom) for providing 2B4
NKG2D reporter cells, Thue W. Schwartz and Siv A. Hjorth for
valuable inputs, and Anni Mehlsen (Department of Veterinary
and Animal Sciences, University of Copenhagen, Denmark) for
technical assistance.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fimmu.
2020.01968/full#supplementary-material
REFERENCES
1. Schmiedel D, Mandelboim O. NKG2D ligands-critical targets for cancer
immune escape and therapy. Front Immunol. (2018) 9:2040. doi: 10.3389/
fimmu.2018.02040
2. Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R, et al.
Major histocompatibility complex class I-related chain A and UL16-binding
protein expression on tumor cell lines of different histotypes: analysis of
tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
Cancer Res. (2002) 62:6178–86.
3. McGilvray RW, Eagle RA, Watson NF, Al-Attar A, Ball G, Jafferji I,
et al. NKG2D ligand expression in human colorectal cancer reveals
associations with prognosis and evidence for immunoediting. Clin
Cancer Res. (2009) 15:6993–7002. doi: 10.1158/1078-0432.ccr-09-
0991
4. Oppenheim DE, Roberts SJ, Clarke SL, Filler R, Lewis JM, Tigelaar RE, et al.
Sustained localized expression of ligand for the activating NKG2D receptor
impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance.
Nat Immunol. (2005) 6:928–37.
5. Coudert JD, Scarpellino L, Gros F, Vivier E, Held W. Sustained NKG2D
engagement induces cross-tolerance of multiple distinct NK cell activation
pathways. Blood. (2008) 111:3571–8.
6. Coudert JD, Zimmer J, Tomasello E, Cebecauer M, Colonna M, Vivier E,
et al. Altered NKG2D function in NK cells induced by chronic exposure to
NKG2D ligand-expressing tumor cells. Blood. (2005) 106:1711–7.
7. Koch C, Kim Y, Zoller T, Born C, Steinle A. Chronic NKG2D engagement
in vivo differentially impacts NK cell responsiveness by activating NK
receptors. Front Immunol. (2017) 8:1466.
8. Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of ligands for
the NKG2D activating receptor. Annu Rev Immunol. (2013) 31:413–41.
9. Warburg O. On the origin of cancer cells. Science. (1956) 123:309–14.
10. Vyas S, Zaganjor E, Haigis MC. Mitochondria and cancer. Cell. (2016)
166:555–66.
11. Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, Dhanak D, et al.
ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell.
(2005) 8:311–21.
12. Zaidi N, Swinnen JV, Smans KATP-citrate lyase: a key player in cancer
metabolism. Cancer Res. (2012) 72:3709–14.
Frontiers in Immunology | www.frontiersin.org 19 August 2020 | Volume 11 | Article 1968
fimmu-11-01968 August 7, 2020 Time: 19:3 # 20
Møller et al. Citrate Facilitates MICA Expression
13. Icard P, Lincet H. The reduced concentration of citrate in cancer cells: an
indicator of cancer aggressiveness and a possible therapeutic target. Drug
Resis. Updat. (2016) 29:47–53. doi: 10.1016/j.drup.2016.09.003
14. Wellen KE, Hatzivassiliou G, Sachdeva UM, Bui TV, Cross JR, Thompson
CBATP–citrate lyase links cellular metabolism to histone acetylation. Science.
(2009) 324:1076–80.
15. Andresen L, Hansen KA, Jensen H, Pedersen SF, Stougaard P, Hansen HR,
et al. Propionic acid secreted from propionibacteria induces NKG2D ligand
expression on human-activated T lymphocytes and cancer cells. J Immunol.
(2009) 183:897–906. doi: 10.4049/jimmunol.0803014
16. McCarthy MT, Moncayo G, Hiron TK, Jakobsen NA, Valli A, Soga T, et al.
Purine nucleotide metabolism regulates expression of the human immune
ligand MICA. J Biol Chem. (2017) 293:3913–24.
17. Fu D, Geschwind JF, Karthikeyan S, Miller E, Kunjithapatham R, Wang
Z, et al. Metabolic perturbation sensitizes human breast cancer to NK
cell-mediated cytotoxicity by increasing the expression of MHC class I chain-
related A/B. Oncoimmunology. (2015) 4:e991228. doi: 10.4161/2162402x.
2014.991228
18. Mellergaard M, Høgh RI, Lund A, Aldana BI, Guérillot R, Møller SH, et al.
Staphylococcus aureus induces cell-surface expression of immune stimulatory
NKG2D ligands on human monocytes. J Biol Chem. (2020). doi: 10.1074/jbc.
RA120.012673
19. Mellergaard M, Skovbakke SL, Schneider CL, Lauridsen F, Andresen L,
Jensen H, et al. N-glycosylation of asparagine 8 regulates surface expression
of major histocompatibility complex class I chain-related protein A (MICA)
alleles dependent on threonine 24. J Biol Chem. (2014) 289:20078–91.
20. Andresen L, Skovbakke SL, Persson G, Hagemann-Jensen M, Hansen KA,
Jensen H, et al. 2-deoxy D-glucose prevents cell surface expression of NKG2D
ligands through inhibition of N-linked glycosylation. J Immunol. (2012)
188:1847–55.
21. Nabi IR, Shankar J, Dennis JW. The galectin lattice at a glance. J Cell Sci.
(2015) 128:2213–9.
22. Dennis JW, Laferté S, Waghorne C, Breitman ML, Kerbel RS. β1-6 branching
of Asn-linked oligosaccharides is directly associated with metastasis. Science.
(1987) 236:582–5.
23. Dennis JW, Laferte S. Oncodevelopmental expression of–GlcNAc beta 1-
6Man alpha 1-6Man beta 1–branched asparagine-linked oligosaccharides in
murine tissues and human breast carcinomas. Cancer Res. (1989) 49:945–50.
24. Demetriou M, Nabi IR, Coppolino M, Dedhar S, Dennis JW. Reduced
contact-inhibition and substratum adhesion in epithelial cells expressing
GlcNAc-transferase V. J Cell Biol. (1995) 130:383–92.
25. Granovsky M, Fata J, Pawling J, Muller WJ, Khokha R, Dennis JW.
Suppression of tumor growth and metastasis in Mgat5-deficient mice. Nat
Med. (2000) 6:306–12.
26. Lau KS, Partridge EA, Grigorian A, Silvescu CI, Reinhold VN, Demetriou
M, et al. Complex N-glycan number and degree of branching cooperate to
regulate cell proliferation and differentiation. Cell. (2007) 129:123–34.
27. Li D, Li Y, Wu X, Li Q, Yu J, Gen J, et al. Knockdown of Mgat5 inhibits
breast cancer cell growth with activation of CD4+ T cells and macrophages. J
Immunol. (2008) 180:3158–65.
28. Morgan R, Gao G, Pawling J, Dennis JW, Demetriou M, Li BN-
. acetylglucosaminyltransferase V (Mgat5)-mediated N-glycosylation
negatively regulates Th1 cytokine production by T cells. J Immunol. (2004)
173:7200–8.
29. Ashiru O, Bennett NJ, Boyle LH, Thomas M, Trowsdale J, Wills MR.
NKG2D ligand MICA is retained in the cis-Golgi apparatus by human
cytomegalovirus protein UL142. J Virol. (2009) 83:12345–54.
30. Lin D, Lavender H, Soilleux EJ, O’Callaghan CA. NF-kappaB regulates MICA
gene transcription in endothelial cell through a genetically inhibitable control
site. J Biol Chem. (2012) 287:4299–310.
31. Reichwald K, Jorgensen TZ, Tougaard P, Skov S. TL1A induces TCR
independent IL-6 and TNF-alpha production and growth of PLZF(+)
leukocytes. PLoS One. (2014) 9:e85793. doi: 10.1371/journal.pone.0085793
32. Steentoft C, Vakhrushev SY, Joshi HJ, Kong Y, Vester-Christensen MB,
Schjoldager KT, et al. Precision mapping of the human O-GalNAc
glycoproteome through SimpleCell technology. Embo J. (2013)
32:1478–88.
33. Steentoft C, Vakhrushev SY, Vester-Christensen MB, Schjoldager KT, Kong
Y, Bennett EP, et al. Mining the O-glycoproteome using zinc-finger nuclease-
glycoengineered SimpleCell lines. Nat Methods. (2011) 8:977–82.
34. Uhlenbrock F, van Andel E, Andresen L, Skov SA. conserved WW domain-
like motif regulates invariant chain-dependent cell-surface transport of the
NKG2D ligand ULBP2. Mol Immunol. (2015) 66:418–27.
35. Uhlenbrock F, Hagemann-Jensen M, Kehlet S, Andresen L, Pastorekova
S, Skov S. The NKG2D ligand ULBP2 is specifically regulated through
an invariant chain-dependent endosomal pathway. J Immunol. (2014)
193:1654–65.
36. Arase H, Mocarski ES, Campbell AE, Hill AB, Lanier LL. Direct recognition
of cytomegalovirus by activating and inhibitory NK cell receptors. Science.
(2002) 296:1323–6.
37. Desler C, Munch-Petersen B, Stevnsner T, Matsui S, Kulawiec M, Singh KK,
et al. Mitochondria as determinant of nucleotide pools and chromosomal
stability. Mutat Res. (2007) 625:112–24.
38. Naz S, Gallart-Ayala H, Reinke SN, Mathon C, Blankley R, Chaleckis R, et al.
Development of a liquid chromatography-high resolution mass spectrometry
metabolomics method with high specificity for metabolite identification
using all ion fragmentation acquisition. Anal Chem. (2017) 89:7933–42.
39. Daskalaki E, Pillon NJ, Krook A, Wheelock CE, Checa A. The influence of
culture media upon observed cell secretome metabolite profiles: the balance
between cell viability and data interpretability. Anal Chim Acta. (2018)
1037:338–50.
40. Mawhinney TP, Robinett RS, Atalay A, Madson MA. Gas-liquid
chromatography and mass spectral analysis of mono-, di- and tricarboxylates
as their tert–butyldimethylsilyl derivatives. J Chromatogr. (1986) 361:117–30.
41. Biemann K. Mass Spectrometry in Organic Chemistry Applications. New York,
NY: McGraw (1962). p. 223e7.
42. Aldana BI, Zhang Y, Lihme MF, Bak LK, Nielsen JE, Holst B, et al.
Characterization of energy and neurotransmitter metabolism in cortical
glutamatergic neurons derived from human induced pluripotent stem cells:
a novel approach to study metabolism in human neurons. Neurochem. Int.
(2017) 106:48–61. doi: 10.1016/j.neuint.2017.02.010
43. Andresen L, Jensen H, Pedersen MT, Hansen KA, Skov S. Molecular
regulation of MHC class I chain-related protein A expression after HDAC-
inhibitor treatment of jurkat T cells. J. Immunol. (2007) 179:8235–42.
44. Buenrostro JD, Giresi PG, Zaba LC, Chang HY, Greenleaf WJ. Transposition
of native chromatin for fast and sensitive epigenomic profiling of open
chromatin, DNA-binding proteins and nucleosome position. Nat Methods.
(2013) 10:1213–8.
45. Liao Y, Smyth GK, Shi W. The Subread aligner: fast, accurate and scalable
read mapping by seed-and-vote. Nucleic Acids Res. (2013) 41:e108. doi: 10.
1093/nar/gkt214
46. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, et al.
Model-based analysis of ChIP-Seq (MACS). Genome Biol. (2008) 9:R137.
47. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a bioconductor package for
differential expression analysis of digital gene expression data. Bioinformatics.
(2010) 26:139–40.
48. Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, et al.
Simple combinations of lineage-determining transcription factors prime cis-
regulatory elements required for macrophage and B cell identities. Mol Cell.
(2010) 38:576–89.
49. Yamada N, Kato-Kogoe N, Yamanegi K, Nishiura H, Fujihara Y, Fukunishi
S, et al. Inhibition of asparagine-linked glycosylation participates in hypoxia-
induced down-regulation of cell-surface MICA expression. Anticancer Res.
(2018) 38:1353–9.
50. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair
expression of NKG2D and T-cell activation. Nature. (2002) 419:734–8.
51. Dennis JW, Lau KS, Demetriou M, Nabi IR. Adaptive regulation at the cell
surface by N-glycosylation. Traffic. (2009) 10:1569–78.
52. Laczy B, Hill BG, Wang K, Paterson AJ, White CR, Xing D, et al. Protein
O-GlcNAcylation: a new signaling paradigm for the cardiovascular system.
Am J Physiol Heart Circ Physiol. (2009) 296:H13–28.
53. Leturcq M, Lefebvre T, Vercoutter-Edouart A-S. O-GlcNAcylation and
chromatin remodeling in mammals: an up-to-date overview. Biochem Soc
Transact. (2017) 45:323–38.
Frontiers in Immunology | www.frontiersin.org 20 August 2020 | Volume 11 | Article 1968
fimmu-11-01968 August 7, 2020 Time: 19:3 # 21
Møller et al. Citrate Facilitates MICA Expression
54. Singh JP, Zhang K, Wu J, Yang X. O-GlcNAc signaling in cancer metabolism
and epigenetics. Cancer Lett. (2015) 356(2 Pt A):244–50.
55. Ferrer CM, Sodi VL, Reginato MJ. O-GlcNAcylation in cancer biology:
linking metabolism and signaling. J Mol Biol. (2016) 428:3282–94.
56. Wellen KE, Lu C, Mancuso A, Lemons JM, Ryczko M, Dennis JW, et al. The
hexosamine biosynthetic pathway couples growth factor-induced glutamine
uptake to glucose metabolism. Genes Dev. (2010) 24:2784–99.
57. Ryczko MC, Pawling J, Chen R, Abdel Rahman AM, Yau K, Copeland JK, et al.
Metabolic reprogramming by hexosamine biosynthetic and golgi N-glycan
branching pathways. Sci Rep. (2016) 6:23043.
58. Abdel Rahman AM, Ryczko M, Nakano M, Pawling J, Rodrigues T, Johswich
A, et al. Golgi N-glycan branching N-acetylglucosaminyltransferases I, V
and VI promote nutrient uptake and metabolism. Glycobiology. (2015)
25:225–40.
59. Johswich A, Longuet C, Pawling J, Abdel Rahman A, Ryczko M, Drucker
DJ, et al. N-glycan remodeling on glucagon receptor is an effector of
nutrient sensing by the hexosamine biosynthesis pathway. J Biol Chem.
(2014) 289:15927–41.
60. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell.
(2011) 144:646–74.
61. Kurtoglu M, Maher JC, Lampidis TJ. Differential toxic mechanisms of 2-
deoxy-D-glucose versus 2-fluorodeoxy-D-glucose in hypoxic and normoxic
tumor cells. Antioxid Redox Signal. (2007) 9:1383–90.
62. Chiaradonna F, Ricciardiello F, Palorini R. The nutrient-sensing hexosamine
biosynthetic pathway as the hub of cancer metabolic rewiring. Cells. (2018)
7:53. doi: 10.3390/cells7060053
63. Olenchock BA, Rathmell JC, Vander Heiden MG. Biochemical
underpinnings of immune cell metabolic phenotypes. Immunity. (2017)
46:703–13.
64. Raud B, Roy DG, Divakaruni AS, Tarasenko TN, Franke R, Ma EH, et al.
Etomoxir actions on regulatory and memory T cells are independent of
Cpt1a-mediated fatty acid oxidation. Cell Metabolism. (2018) 28:504–15.e7.
65. Potapova IA, El-Maghrabi MR, Doronin SV, Benjamin WB. Phosphorylation
of recombinant human ATP:citrate lyase by cAMP-dependent protein kinase
abolishes homotropic allosteric regulation of the enzyme by citrate and
increases the enzyme activity. Allosteric activation of ATP:citrate lyase by
phosphorylated sugars. Biochemistry. (2000) 39:1169–79.
66. Venkataraman GM, Suciu D, Groh V, Boss JM, Spies T. Promoter region
architecture and transcriptional regulation of the genes for the MHC Class
I-related chain A and B ligands of NKG2D. J. Immunol. (2007) 178:961–9.
67. Merkenschlager M, Odom DT. CTCF and cohesin: linking gene regulatory
elements with their targets. Cell. (2013) 152:1285–97.
68. Loukinov D. Targeting CTCFL/BORIS for the immunotherapy of cancer.
Cancer Immunol Immunother. (2018) 67:1955–65.
69. Zhang D, Tang Z, Huang H, Zhou G, Cui C, Weng Y, et al. Metabolic
regulation of gene expression by histone lactylation. Nature. (2019)
574:575–80.
70. Chang CH, Curtis JD, Maggi LB Jr., Faubert B, Villarino AV, O’Sullivan
D, et al. Posttranscriptional control of T cell effector function by aerobic
glycolysis. Cell. (2013) 153:1239–51.
71. Tang M, Etokidem E, Lai K. The leloir pathway of galactose metabolism - a
novel therapeutic target for hepatocellular carcinoma. Anticancer Res. (2016)
36:6265–71.
72. Zhdanov AV, Waters AH, Golubeva AV, Dmitriev RI, Papkovsky DB.
Availability of the key metabolic substrates dictates the respiratory response
of cancer cells to the mitochondrial uncoupling. Biochim Biophys Acta. (2014)
1837:51–62. doi: 10.1016/j.bbabio.2013.07.008
73. Molinero LL, Fuertes MB, Rabinovich GA, Fainboim L, Zwirner NW.
Activation-induced expression of MICA on T lymphocytes involves
engagement of CD3 and CD28. J Leukoc Biol. (2002) 71:791–7.
74. Skov S, Pedersen MT, Andresen L, Straten PT, Woetmann A, Odum N.
Cancer cells become susceptible to natural killer cell killing after exposure to
histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent
expression of MHC class I-related chain A and B. Cancer Res. (2005)
65:11136–45.
75. Gerriets VA, Rathmell JC. Metabolic pathways in T cell fate and function.
Trends Immunol. (2012) 33:168–73.
76. Vander Heiden MG. Targeting cancer metabolism: a therapeutic window
opens. Nat Rev Drug Discov. (2011) 10:671–84.
77. McSharry BP, Burgert HG, Owen DP, Stanton RJ, Prod’homme V, Sester
M, et al. Adenovirus E3/19K promotes evasion of NK cell recognition by
intracellular sequestration of the NKG2D ligands major histocompatibility
complex class I chain-related proteins A and B. J. Virol. (2008)
82:4585–94.
78. Yamamoto E, Ino K, Miyoshi E, Shibata K, Takahashi N, Kajiyama
H, et al. Expression of N-acetylglucosaminyltransferase V in
endometrial cancer correlates with poor prognosis. Br J Cancer. (2007)
97:1538–44.
79. Kim YS, Hwang SY, Kang HY, Sohn H, Oh S, Kim JY, et al. Functional
proteomics study reveals that N-Acetylglucosaminyltransferase V
reinforces the invasive/metastatic potential of colon cancer through
aberrant glycosylation on tissue inhibitor of metalloproteinase-1.
Mol Cell Proteomics. (2008) 7:1–14. doi: 10.1074/mcp.m700084-mcp
200
80. Dias AM, Correia A, Pereira MS, Almeida CR, Alves I, Pinto V,
et al. Metabolic control of T cell immune response through glycans
in inflammatory bowel disease. Proc Natl Acad Sci USA. (2018)
115:E4651–60.
81. Partridge EA, Le Roy C, Di Guglielmo GM, Pawling J, Cheung P, Granovsky
M, et al. Regulation of cytokine receptors by Golgi N-glycan processing and
endocytosis. Science. (2004) 306:120–4.
82. Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism.
Cell Metab. (2016) 23:27–47. doi: 10.1016/j.cmet.2015.12.006
83. Li X, Wenes M, Romero P, Huang SC-C, Fendt S-M, Ho P-C. Navigating
metabolic pathways to enhance antitumour immunity and immunotherapy.
Nat Rev Clin Oncol. (2019) 16:425–41.
84. Zhang X, Rao A, Sette P, Deibert C, Pomerantz A, Kim WJ, et al.
IDH mutant gliomas escape natural killer cell immune surveillance
by downregulation of NKG2D ligand expression. Neuro Oncol. (2016)
18:1402–12.
85. Giskeodegard GF, Bertilsson H, Selnaes KM, Wright AJ, Bathen TF, Viset T,
et al. Spermine and citrate as metabolic biomarkers for assessing prostate
cancer aggressiveness. PLoS One. (2013) 8:e62375. doi: 10.1371/journal.pone.
0062375
86. Ren JG, Seth P, Ye H, Guo K, Hanai JI, Husain Z, et al. Citrate
suppresses tumor growth in multiple models through inhibition of glycolysis,
the tricarboxylic acid cycle and the IGF-1R pathway. Sci Rep. (2017)
7:4537.
87. Balmer ML, Ma EH, Bantug GR, Grahlert J, Pfister S, Glatter T, et al. Memory
CD8(+) T cells require increased concentrations of acetate induced by stress
for optimal function. Immunity. (2016) 44:1312–24.
88. Khwairakpam AD, Shyamananda MS, Sailo BL, Rathnakaram SR,
Padmavathi G, Kotoky J, et al. ATP citrate lyase (ACLY): a promising
target for cancer prevention and treatment. Curr. Drug Targets. (2015)
16:156–63.
89. Hanai JI, Doro N, Seth P, Sukhatme VP. ATP citrate lyase knockdown impacts
cancer stem cells in vitro. Cell Death Dis. (2013) 4:e696. doi: 10.1038/cddis.
2013.215
90. Sheppard S, Ferry A, Guedes J, Guerra N. The paradoxical role of NKG2D in
cancer immunity. Front Immunol. (2018) 9:1808.
91. Sheppard S, Guedes J, Mroz A, Zavitsanou AM, Kudo H, Rothery SM,
et al. The immunoreceptor NKG2D promotes tumour growth in a model of
hepatocellular carcinoma. Nat Commun. (2017) 8:13930.
92. Eidelman E, Twum-Ampofo J, Ansari J, Siddiqui MM. The metabolic
phenotype of prostate cancer. Front Oncol. (2017) 7:131.
93. Mladenova V, Mladenov E, Russev G. Organization of Plasmid DNA into
nucleosome-like structures after transfection in eukaryotic cells. Biotechnol.
Biotechnolog. Equip. (2009) 23:1044–7.
94. Pietrocola F, Galluzzi L, Bravo-San Pedro JM, Madeo F, Kroemer G. Acetyl
coenzyme A: a central metabolite and second messenger. Cell Metab. (2015)
21:805–21.
95. Sivanand S, Rhoades S, Jiang Q, Lee JV, Benci J, Zhang J, et al. Nuclear Acetyl-
CoA production by ACLY promotes homologous recombination. Mol Cell
(2017) 67:252–65.e6.
Frontiers in Immunology | www.frontiersin.org 21 August 2020 | Volume 11 | Article 1968
fimmu-11-01968 August 7, 2020 Time: 19:3 # 22
Møller et al. Citrate Facilitates MICA Expression
96. Sutendra G, Kinnaird A, Dromparis P, Paulin R, Stenson TH, Haromy A, et al.
A nuclear pyruvate dehydrogenase complex is important for the generation
of acetyl-CoA and histone acetylation. Cell. (2014) 158:84–97. doi: 10.1016/j.
cell.2014.04.046
97. Sivanand S, Viney I, Wellen KE. Spatiotemporal control of Acetyl-CoA
metabolism in chromatin regulation. Trends Biochem Sci. (2018) 43:61–74.
98. Hogh RI, Droujinine A, Moller SH, Jepsen SD, Mellergaard M, Andresen
L, et al. Fumarate upregulates surface expression of ULBP2/ULBP5
by scavenging glutathione antioxidant capacity. J Immunol. (2020)
204:1746–59.
99. Caillat-Zucman S. How NKG2D ligands trigger autoimmunity? Hum
Immunol. (2006) 67:204–7.
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Møller, Mellergaard, Madsen, Bermejo, Jepsen, Hansen, Høgh,
Aldana, Desler, Rasmussen, Sustarsic, Gerhart-Hines, Daskalaki, Wheelock, Hiron,
Lin, O’Callaghan, Wandall, Andresen and Skov. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice. No
use, distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Immunology | www.frontiersin.org 22 August 2020 | Volume 11 | Article 1968
